Beta Drugs Ltd (NSE: BETA) - Aamara Capital Research

Beta Drugs Ltd NSE: BETA · Snapshot as of 13 Oct 2026

FY26 Revenue from ops₹384.8 Cr+6.2% YoY [Fact]

FY26 PAT₹41.5 Cr−2.2% YoY; 10.8% margin

FY26 EBITDA margin (ex-OI)19.7%₹75.7 Cr; deck 22.6% incl. OI

FY26 RoE / RoCE18.8% / 19.2%reported basis; 12.4% RoE with CCD as equity

Q1 FY27 Revenue₹125.6 Cr+25.3% YoY (~10% organic ex-Nivian)

Q1 FY27 PAT₹16.5 Cr+41%; owners ₹15.8 Cr +35%

Branded oncology Q1 FY27+47%₹33.0 Cr vs ₹22.4 Cr

Net cash ex-CCD (Mar-26)₹87 CrCash ₹124.8 Cr vs bank debt ₹37.8 Cr

Quick verdict scorecard

Business

Medium

Branded oncology is strong (35–36% margin). CDMO and tender exports are weak.

Management

Weak

Guidance cut 3 times, promoter sold before the cut, MDs paid by two entities, audit is thin

Financial

Medium

Net cash, but CCC 53→100 days and FY26 FCF −₹16 Cr

Valuation

Expensive

~41x P/E vs 13–35x for peers. Close to its own 3-yr average (~39x).

Overall

Neutral

Watch Q2 FY27, the NPPA final notice and the EU-GMP outcome

Market data

Item	Value
CMP 13 Oct 2026 (intraday; no close in sources)	₹1,684 (Screener 2:34 pm, −8.7%); ₹1,669 (2:49 pm, −9.5%)
Previous session 12 Oct	−4.6%
Shares, fully diluted (incl. 35,383 bonus true-up shares, Aug-26)	1,11,21,255
Market cap (on the share count above)	₹1,856–1,873 Cr
52-week high / low	₹2,807.9 (12 Aug 26) / ₹990.1 (25 Feb 26)
Off 52-week high	~−40%
P/E TTM (consolidated owners' PAT ₹45.6 Cr)	~41x (40.7–41.1x)
EV/EBITDA TTM	~22x (21.9–22.2x)
P/B (book after conversion, ~₹377/sh)	~4.4x
Dividend yield / buybacks	0% / none, ever
Returns 3m / 6m / 1y / 3y / 5y (MarketsMojo)	−29.0% / +19.1% / −3.0% / +76.9% / +199%
Index membership	None (left Nifty SME Emerge 24 Nov 2025)
Shareholders (Jun-26)	7,359 (Sep-25: 3,184)
Average volume (TipRanks)	~13,000 sh/day

Company overview

Item	Detail
CIN	L24230HP2005PLC028969; incorporated 21 Sep 2005 (HP); became a public company 11 Aug 2017
Registered office / plant	Vill. Nandpur, Lodhimajra Rd, Baddi, Distt Solan, HP 174101
Corporate office	SCO-184, Sector 5, Panchkula, leased from BT Associates (promoter group); export office at Peninsula Park, Andheri W, Mumbai
Group	Adley Group, founded 1985 by the late Vijay Kumar Batra (died 23 Jan 2021)
Promoters	Mrs Neeraj Batra (58.40%); Rahul Batra (CMD); Varun Batra (Jt MD), brothers
Sector	Pharma: oncology formulations (branded, CDMO, exports), API, derma, IVF
Employees	455 permanent at standalone BDL (FY26; FY25: 399)
Subsidiaries	Adley Formulations (99.99%), Adley Lab (99.99%), Beta Research (dormant), Nivian Lifesciences (66.09%, from Apr-26)
Auditor	Khurana Sharma & Co (Chandigarh). Subsidiaries are audited by Kalra Rai & Associates.
Credit rating	CRISIL BBB+/Positive (advisory 25 Sep 2026); Brickwork A-/Stable (6 Jul 2026)
IR	Valorem Advisors (Anuj Sonpal)

What the company does. Beta Drugs is a Baddi-based oncology drug maker in the Batra family's Adley Group. It makes cytotoxic and targeted cancer medicines as tablets, capsules, oral liquids, liquid and lyophilised injections, and prefilled syringes. It sells them through four channels: its own "Adley" brands to Indian hospitals (36% of FY26 revenue); contract manufacturing for companies such as Glenmark, Intas, Alkem, Cadila and Torrent (39%); tender exports to about 40 emerging-market countries (18%); and third-party API sales from its Adley Lab subsidiary (7%). It has also added dermatology (in-licensed from Italy and Greece) and, since April 2026, IVF drugs through a 66% stake in Nivian Lifesciences. FY26 consolidated revenue was ₹384.8 Cr and PAT ₹41.5 Cr. About 65% of that profit is earned in subsidiaries. [Fact]

Data freshness: prices are Screener/MarketsMojo intraday figures from 13 Oct 2026. Financials run to Q1 FY27 (results of 20 Jul 2026). Shareholding is the Jun-26 quarter; the Sep-26 pattern is due ~21 Oct 2026. Q2 FY27 results have not been announced; the trading window has been closed since 1 Oct 2026.

Analyst Notes

Reconciliations: the figure this report uses, and the alternatives

#	Issue	Figure used in this report	Alternative and why it differs	Label
1	Valuation	P/E ~41x trailing consolidated (TTM owners' PAT ₹45.6 Cr, FD mcap ₹1,856–1,873 Cr); 3-yr average ~39x. EV/EBITDA ~22x (TTM EBITDA ₹83.3 Cr). P/B ~4.4x on book after conversion (~₹419 Cr, ₹377/sh).	heard.md (Screener page) shows P/E ~117x, P/B ~11.7x and RoE ~10%. Those are on the standalone entity: standalone FY26 PAT is ₹14.3 Cr, only 35% of group PAT (₹1,867 Cr ÷ ₹14.3 Cr ≈ 130x). The forum's "60–145x" mixes standalone figures with book value before conversion. Screener's consolidated P/B of 7.0–7.2x uses the stale ₹241/sh book before the CCD conversion. MarketsMojo shows 45x / 8.35x / 27.3x on its own basis.	[Est.]
2	FY26 revenue and EBITDA	Revenue from operations ₹384.8 Cr (+6.2%). EBITDA excluding other income ₹75.7 Cr (19.7%).	Management's "₹396 Cr net revenue" is total income (includes ₹11.2 Cr of other income, of which ₹9.9 Cr is FD interest). The deck's "₹86.85 Cr / 22.57%" EBITDA includes other income (75.67 + 11.18).	[Fact]
3	Promoter sale	Confirmed (FY26 AR Note 11b). Neeraj Batra went from 66,58,746 to 64,73,631 shares, i.e. 1,85,115 shares sold. Bulk deal on 13 Nov 2025 at ₹1,686 (~₹31.2 Cr); Airavat Capital Trust II bought 1,55,925. Promoter holding 66.73% → 64.90% → 64.63% → 59.10%.	Share counts reconcile every step: 65,51,392 ÷ 1,00,94,553 = 64.90% (Dec-25, before the 42,337-share conversion was counted); ÷ 1,01,36,890 = 64.63% (Mar-26: the 42,337 CCD conversion, not a further sale); ÷ 1,10,85,872 = 59.10% (Jun-26: dilution from 6,65,314 CCD shares + 2,83,668 Nivian swap shares). governance.md's "~27,000 sold in the Mar quarter" is therefore wrong, and narrative.md's "unconfirmed" is superseded. Neeraj Batra's 63.86% (Mar-26, ÷1.0137 Cr shares) and 58.40% (Jun-26, ÷1.1086 Cr) are the same 64,73,631 shares over different share counts. On 1,11,21,255 shares she holds 58.2% and the promoter group 58.9%.	[Fact]
4	Q1 FY27 organic growth	~10.2% = (125.5 − 15.1 Nivian) ÷ 100.2	market.md gives "~14% ex-Nivian" without a method. It would only reconcile if Nivian added about ₹11.4 Cr, not ₹15.1 Cr. Not adopted.	[Est.] / 14%: [Est., method not disclosed]
5	MD pay	Rahul and Varun Batra each draw ₹1.51 Cr from Beta and ₹1.51 Cr from Adley Formulations, so ~₹3.02 Cr each. Group executive-director pay is ~₹6.8 Cr, ≈16% of consolidated PAT.	The s.197(12) table shows only the Beta half (49.05x median). Beta-paid ED pay of ₹3.81 Cr is ~27% of standalone PAT. Special resolutions were passed (20th AGM 30 Sep 2025; 19th AGM 2024), so this is not a breach.	[Fact]
6	Credit rating	CRISIL BBB+/Positive (reaffirmed 20 Jan 2026 on ₹8 Cr). On 25 Sep 2026 CRISIL issued an advisory that it is "awaiting adequate information", which is not a reaffirmation. Brickwork BWR A-/Stable and A2 assigned on 6 Jul 2026 on ₹42.89 Cr.	Brickwork had the company as "Issuer Not Cooperating" from 17 Jun 2020 to Jul 2026 (B+ INC Jan-24, B INC Apr-25). The FY26 CG report shows only Brickwork, as "No change", and omits CRISIL. Brickwork is also the monitoring agency for the CCD money.	[Fact]
7	NPPA trade-margin cap	8 Oct 2026: NPPA gave in-principle approval to a 30%-of-MRP trade-margin cap on ~110 non-scheduled anti-cancer drugs. The Supreme Court floated a uniform 16% on 29 Sep 2026.	A possible trigger for the 12–13 Oct fall (−4.6%, then −8.7/−9.5%; Shilpa −4.4%). Offset: on 11 Jun 2026 NPPA raised carboplatin and cisplatin ceilings by 50%.	[Inferred]
8	₹117 Cr CCD	₹93.13 Cr unused at 31 Mar 2026 (only ₹23.87 Cr used) while carrying a 7.8% coupon (₹9.36 Cr in FY26). All converted by 25 May 2026. Brickwork is the monitoring agency.	Conversion price ₹1,653.40 [Fact]. That is ~₹1,575 adjusted for the bonus; narrative.md's ₹1,643 is a source error.	[Fact]
9	Kacholia stake	~11.0%: 4.91% direct + 6.13% via Suryavanshi Commotrade	The Suryavanshi–Kacholia link is from heard.md/Trendlyne only. The AR and governance.md cannot identify the holder. governance.md infers Kacholia sold ~39,000 shares in Q1 FY27; heard.md says the fall was dilution only.	[Inferred]

The read

1. The core franchise is real. Domestic branded oncology grew from ₹82 Cr (FY24) to ₹103 Cr (FY25) and ₹123 Cr (FY26), then rose 47% to ₹33 Cr in Q1 FY27. Management puts its EBITDA margin at 35–36%. It sells 135+ products, reaches 85%+ of India's corporate and government hospitals, and has first-in-India NDDS oral liquids (Caxfila-OS ~₹10 Cr, the #1 brand; Adxate-OS methotrexate solution launched Apr-26). Consolidated gross margin has moved from 50.4% (Q1 FY26) to 55.5% (FY26) and 56.6% (Q1 FY27). If Beta were only this business, it would deserve a premium multiple. [Analyst View]

2. Management's forecasting is the problem. In May 2025 management talked about "₹750 odd crores by FY28" and did not push back on an analyst's ₹450 Cr for FY26. By Nov 2025 it said it "never gave ₹450 crores". In Feb 2026 it cut the FY26 guide from ₹420 Cr to ₹400 Cr. The actual was ₹384.8 Cr, +6.2%. Exports, guided at ">₹100 Cr in H2 FY26", delivered ~₹28 Cr. The EU-GMP inspection has slipped five times (Dec-23 → before Mar-25 → Oct–Dec 25 → Jan–Mar 26 → Sep-26), and no outcome has been announced. The FY27 guide went from ₹530 Cr at ~24% EBITDA (Feb-26) to "20–25% growth" (~₹462–481 Cr) without being called a cut. Each miss was put down to an outside cause: rains, audits, GST, NPPA, LatAm geopolitics.

3. Promoter selling came before the bad news. The FY26 AR confirms that Neeraj Batra sold 1,85,115 shares (~₹31 Cr at ₹1,686) on 13 Nov 2025. That was six days after the 7 Nov call had already trimmed growth guidance to 20–25%, eleven days before the Main Board listing, and about three months before the 14 Feb guidance cut that sent the stock down 19.6% intraday to ₹1,105. The buyer, Airavat (an AIF), is roughly at breakeven today. The sale is small (~1.8% of equity, below the SAST trigger), but the timing is poor.

4. Cash conversion has not kept up with profit. The cash conversion cycle went from 53 days (FY22) to 100 days (FY26); inventory days on COGS went from 87 to 159. OCF/EBITDA has been 0.44–0.52x for four years. FCF was −₹0.7 Cr in FY25 and −₹16.2 Cr in FY26, including ₹25.9 Cr of land; over five years cumulative FCF is ~₹18 Cr against PAT of ₹176 Cr. Meanwhile ₹93 Cr of the ₹117 Cr raise sat in deposits earning ~₹9.9 Cr while the CCD coupon cost ₹9.4 Cr.

5. Governance is weak. The two MDs draw ₹3.02 Cr each across Beta and Adley Formulations. The Directors' Report table shows only half of it. The statutory audit fee is ₹4.2 lakh, the report has no Key Audit Matters, and there is no other-auditor paragraph even though all subsidiaries are audited by a different firm. Adley Lab sells 69% of its output to group companies at transfer prices. The title to Adley Formulations' Barotiwala plant land sat in the deceased founder's proprietorship name, with a writ pending; the FY26 AR dropped the disclosure without explanation. A directors' partnership firm, Rishi Herbal Products, supplies the group. CRISIL says it is awaiting information. None of these is fraud. Together they argue against paying a high multiple.

6. There is a new regulatory risk. On 8 Oct 2026 NPPA gave in-principle approval to a 30% trade-margin cap on ~110 non-scheduled anti-cancer drugs (MRP cuts of 20–70%), with the Supreme Court floating 16%. That targets hospital-channel branded generics, which is exactly where Beta's best business sits. The cap leaves the manufacturer's price unchanged on paper, but hospitals that lose their spread will push back on purchase prices or switch brands. I think this is the most likely reason for the 12–13 Oct sell-off [Inferred]. The June 2026 50% rise in platin ceilings partly offsets it by reviving a ₹30–35 Cr platin line.

7. What supports the stock. Net cash is ~₹87 Cr (Mar-26, ex-CCD). The CCDs converted, so ₹9.4 Cr a year of coupon goes away. The holder register is strong: HealthQuad (healthcare PE, board nominee), Inti Capital, Airavat, and Kacholia-linked holdings of ~11% [Inferred]. These investors paid ₹1,575–1,712 a share (CCDs bonus-adjusted ~₹1,575; Airavat ₹1,686; Nivian swap ₹1,712), and the stock is now ₹1,669–1,684, back at their cost. On FY27 guidance, EV/EBITDA falls to ~17–18x.

8. What to watch. Q2 FY27 results (expected early-to-mid Nov 2026): exports need to run at ~₹30 Cr a quarter to reach the ₹105–110 Cr FY27 guide, and branded growth must hold above 20%. Then the EU-GMP outcome, the final NPPA notification and drug list (DGHS list was due 14 Oct), and Beta's exposure to non-scheduled molecules, which has not been disclosed. My stance is Neutral: a good franchise inside a company whose numbers and governance need constant checking, at a multiple that leaves little room for another miss. [Analyst View]

Business Deep-Dive

An oncology-focused specialty pharma group, backward-integrated into oncology APIs. It added derma/cosmetology in 2023 and IVF in 2026, and has five revenue verticals across three manufacturing entities and one marketing subsidiary. The group traces back to Vijay Batra's Adley Formulations proprietorship (oncology unit from 2008). Vijay Batra took over Beta Drugs Pvt Ltd in 2014 from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal and refocused it on oncology.

Products by vertical

Vertical	FY26 ₹ Cr	Share	What it is
Branded oncology ("Adley" brands)	123.2	32%	135+ products and 180+ oncology SKUs (220+ group-wide): cytotoxics, TKIs ("nibs/mibs"), hormonal and supportive care. Tablets, capsules, liquid and lyophilised injections, prefilled syringes and oral liquids
Derma / cosmetology	16.6	4%	24 SKUs (Nov-25) or 40+ with 9 in development (Jul-26). In-licensed products from Promoitalia (Italy) and Frezyderm (Greece)
CMO / CDMO	149.4	39%	Cytotoxic and oncology formulations for Indian brand owners
Exports	70.9	18%	Own registered generics sold via public tenders and distributors in ~40–46 countries
API (external)	24.8	7%	Adley Lab oncology APIs and intermediates
IVF (Nivian, from Q1 FY27)	— (₹15.1 Cr in Q1 FY27)	—	31 fertility products, made by 11 contract manufacturers
Consolidated	384.8	100%

Named brands and molecules

Class	Brands (molecule)
Platins / taxanes	Adcarb (carboplatin), Adcist (cisplatin), Adplatin (oxaliplatin), Adpaxil (paclitaxel), AB-Pacli (nano albumin-bound paclitaxel, developed in-house in 2015)
Other cytotoxics	Adben-100 (bendamustine, lyophilised), Adxate (methotrexate injection), Adthal (thalidomide); ready-to-use docetaxel and gemcitabine
TKIs	Adgef (gefitinib), Adtrinib (sorafenib), Adlante (lenvatinib), Kabonib (cabozantinib), Kynolib (nilotinib), Pazotab (pazopanib); olaparib, erlotinib, imatinib
Hormonal / other	Adbiron (abiraterone), Adcumin
NDDS / first-in-India	Caxfila-OS (megestrol oral suspension): grew the molecule's market from ₹6 Cr to ₹16 Cr; #1 brand at ~₹9–10 Cr. Adxate-OS (methotrexate 2 mg/ml oral solution): DCGI first approval Oct-25, launched Apr-26 after NPPA fixed the price. Crizenta (crizotinib 200 mg). Pipeline: imatinib oral solution; one NDDS in BE with CDSCO, approval expected Jan–Feb 2027; capecitabine OS
Derma brands	Clinzap, Idera (itraconazole 200), La'Thrix, Nupellis, Nusplash, Sensibar, Urticalm, Uvirex; Promoitalia fillers and mesotherapy (registered 2025; mesotherapy approved Apr-26); Frezyderm anti-ageing and depigmentation; 8+ EU products in registration

Brand and field metrics	Value
Top-10 brands, share of own-brand sales	>50%
Orals, share of own-brand sales	~48%
Brands above ₹5 Cr	7 (6 expected in FY26)
New products as % of FY26 sales	25%; 13 launches in FY25–26
Oncology coverage by sub-segment (management)	Cytotoxic 84%, nib/mib 65%, hormonal 62%, supportive care 26%
Field force	Three oncology divisions (haematology; supportive care + uro-oncology; solid tumour); 66+ territory managers (deck). Derma: 69 TMs at ₹1.85 lakh/TM/month (target ₹2.3–2.4 lakh)
Derma prescribers	1,200 → 2,600 in FY25; revenue per prescriber ₹75k → ₹1.25 lakh

Nivian Lifesciences (IVF, 66.09%)

Item	Detail
Office / founder	Omega Business Park, Wagle Estate, Thane. Founder Nilesh Auti (ex-Bharat Serums & Vaccines) keeps ~33.9% and runs the business. Business "founded 2019"; the company was incorporated 18 Mar 2024 (governance.md). Both are shown because the inputs conflict.
Consideration	₹69.40 Cr for 66.09% at ~₹105 Cr valuation: ₹20.82 Cr cash + 2,83,668 BDL shares at ₹1,712.49 (₹48.58 Cr)
Revenue	Deck: FY24 ₹21.0 Cr → FY25 ₹35.0 Cr → FY26 ₹43.0 Cr (management also cites ₹45–46 Cr). Audited FY25: ₹29.12 Cr revenue, EBITDA ₹4.22 Cr. 9M FY26 ₹30.3 Cr.
Margins	EBITDA 18–19%; PAT 9–10%
Valuation paid	~3.6x FY25 sales, ~25x FY25 EBITDA, ~23–26x PAT [Est.]
Operations	31 products from 11 third-party manufacturers; 15 states/UTs; 61 sales staff (deck), or 90 account managers (other source); 1,500+ fertility clinics, 1,500+ IVF labs, 500 IUI clinics, 1,209 gynaecologists (~3,000 IVF specialists per another source)
Concentration	Top-5 brands ₹29.9 Cr; top brand ₹9.3 Cr (~22%)
Market	~4.5% of a ~₹2,000 Cr IVF-drug market (→ ₹3,800 Cr by FY30, ~17% CAGR). Absent from the ~₹1,000 Cr recombinant segment (in-licensing planned); 4 launches in FY27. Q1 FY27: ₹15.1 Cr, +45%

CMO, exports, API, R&D

Area	Detail
CMO clients (deck)	Glenmark, Cadila Pharmaceuticals, RPG Life Sciences, Alkem, Intas, Torrent, Amneal, Eris, Hetero Healthcare, Reliance Life Sciences, Shilpa, Caplin Point. Historical (CRISIL 2020): Zydus Healthcare, Intas, Torrent, Cadila Healthcare, Hetero
CMO metrics	"~30 CDMO players" (May-25 call) vs "104+ clients" (Jul-26 deck, probably all B2B accounts); 14 projects in development; 95% repeat business; "not lost a single CDMO partner"; international CMO planned after EU-GMP
Export mix FY26	LATAM 42%, APAC 32%, Africa 19%, MENA 7%; ~90% of oncology demand outside India is bought by tender
LATAM markets	Belize, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru, Saint Martin, Venezuela
MENA / CIS	Algeria, Azerbaijan, Belarus, Egypt, Georgia, Jordan, Mauritius, Morocco, Syria, Yemen
Africa	Ethiopia, Ivory Coast, Kenya, Nigeria, Tanzania, Uganda, Zimbabwe
APAC / CIS	Kazakhstan, Mongolia, Myanmar, Nepal, Philippines, Russia, Sri Lanka, Uzbekistan
Registrations	166 approved products, 280 registrations. Pipeline of 623 (LATAM 220, MENA 157, APAC 105, CIS 88, Africa 53); ">600 filings over FY27–28" (AR)
Export scale	₹46.0 Cr (FY24) → ₹79.5 Cr (FY25, +72.7%) → ₹70.9 Cr (FY26, −10.8%) → ₹17.2 Cr (Q1 FY27). FY26 standalone BDL ₹67.7 Cr (+6% FOB vs ₹63.8 Cr); AFPL ₹3.1 Cr (FY25 ₹15.7 Cr)
API (Adley Lab)	Standalone revenue ₹80.0 Cr, all domestic. ₹55.3 Cr (69%) to group (BDL ₹26.0 Cr, AFPL ₹29.3 Cr). External ₹24.8 Cr. 3 APIs in development; 20 molecules over 3–5 years
R&D / IP	2 patents; 80 products developed in total. Pipeline 24 products over FY27–29 (10/7/7); 8 molecules as first or second generics in regulated markets; ~₹15 Cr BE budget for 11 orals; NDDS platforms (liposomes, nanoparticles, microparticles). Standalone R&D spend ₹2.04 Cr (FY25 ₹1.02 Cr), <1% of revenue; consolidated R&D consumables ₹3.59 Cr. Management's "almost 2%" is not supported. R&D team ~10; regulatory team 17–18, being doubled. Biosimilar in-licensing NDAs signed (Nov-25); launch 3–4 years away

How it is made

Step	Detail
1. KSM → intermediate → API (Adley Lab, Derabassi)	Multi-step synthesis from N-2/N-3 intermediates and KSMs imported mainly from China. FY26: bought an existing licensed chemical plant 50–70 m away for ~₹9.45 cr (land additions ₹9.78 cr), avoiding 3–5 years of NGT clearances. Intermediate plant costs ~₹27 Cr in total; the AR cites ₹10.45 Cr spent + ₹25 Cr planned, operational by end-Q3 FY27 (management: "end-CY2026"). Aims: DMF control, lower import dependence, +1–1.5pp margin, sale of surplus intermediates
2. Formulation (two Baddi-area plants)	Contained cytotoxic oral solids, oral liquids, sterile liquids, lyophilised vials and PFS (AFPL). FY26 realignment: AFPL (Barotiwala) = domestic branded + CMO; BDL (Nandpur) = exports and regulated markets (still makes ~20–25% of domestic supply). Management calls Nandpur the "first cytotoxic suspension plant to be inspected by Europe"
3. Inputs	Chemicals, salts and APIs; excipients and packing (vials, stoppers, blisters); petrochemical solvents (~5 months' buffer); power and DG sets (₹9.7 Cr). FY26 consolidated material cost ₹173.8 Cr on purchases of ₹185.9 Cr
4. Outsourced	Derma imports; Nivian's 11 CMOs (may move onto Beta's lines)
5. Systems	Group ERP cloud-hosted by TCS

Facilities

#	Plant	Location	Products	Installed capacity (Jul-26 deck)	Util.	Certifications
1	Beta Drugs (built 2014)	Vill. Nandpur, Lodhimajra Rd, Baddi HP 174101	Orals, oral liquids, liquid and lyo injectables; export plant	3.0 mn liquid inj; 0.5 mn lyo; 50 mn tabs; 10 mn caps	67.3%	WHO-GMP, EAEU, INVIMA, COFEPRIS, ANVISA, PIC/S; Azerbaijan inspection 13–17 Apr 2026; EU-GMP pending
2	Adley Formulations (inc. 2018; unit since 2008)	Vill. Kotla, PO Barotiwala, Solan HP 174103	Tabs, caps, liquid and lyo injections, PFS; domestic and CMO	1.5–3.3 mn liquid; 1.0–6.3 mn lyo; 15–35 mn tabs; 5–8 mn caps; 9 mn PFS	69.9%	WHO-GMP
3	Adley Lab (inc. 1992; acquired Oct-2019)	Plot D-27, Industrial Focal Point, Derabassi, Punjab 140507; warehouse C8	Oncology APIs and intermediates	Line 1 60 TPA; Line 2 30 TPA (2021: 5+60; line added FY25)	79.4%	WHO-GMP; PIC/S (via COFEPRIS inspection)
4	Intermediate/KSM plant (acquired FY26)	Adjacent to Adley Lab	Captive KSMs and intermediates	n.d.	build-out	Licensed site
5	Offices / land	SCO-184 Panchkula (rent ₹2.41 lakh/month to BT Associates); AFPL showroom SCO-42 Panchkula; Plot 38 Ph II Panchkula (~1,000 m², UCO mortgage), bought for an R&D centre, plan dropped, to be sold	—	—	—	—

Line utilisation (May-26 call): orals 40–45%; liquid injectables 60–65%; lyophilisation ~85%, so 2 lyophilisers will be added. Management says current assets support ₹700–800 Cr of revenue; capex ≤₹25 Cr over FY27–28. Nandpur land parcels (9 Bigha 15 Biswa; 4B 4B; 5B 11B) are mortgaged to HDFC, SIDBI and ICICI. An earlier 2018 "oncology plant in Uzbekistan" was a Beta UBK International investment, now carried at nil (forum: 60% owned, non-operational).

Regulatory approvals and market access

Approval	Status
WHO-GMP	All three plants
COFEPRIS (Mexico)	Audit Mar-25 (cost ~10 production days, ₹7–8 Cr of sales); re-audit done H1 FY26. 16–23 dossiers filed; oncology market ~US$140 mn
INVIMA (Colombia)	Injectables cleared H1 FY26; 10 dossiers by year-end
ANVISA, EAEU, PIC/S	Held (Nandpur); Adley Lab PIC/S
Kenya GMP (2016); ZaZiBoNa (SADC, FY25)	Held (plant not specified)
Philippines	2 CPRs, both first generics (Apr-26); Vietnam and Thailand next
Azerbaijan	GMP inspection Apr-26; product approvals 22 Sep 2026; 15 dossiers filed + 15 due; sales planned FY27
Others	Algeria, South Africa (4 dossiers), Colombia, Central America, Jordan
EU-GMP	Target slipped: Dec-23 → before Mar-25 → Oct–Dec 25 → Jan–Mar 26 → "Sep first week" 2026 (new rule requires dossiers before inspection; 3 EU dossiers filed). No outcome announced as of early Oct 2026. EU revenue ~2.5 years after approval. EU-GMP has been an IPO object since 2017 (₹0.79 Cr)
ISO / IATF / AS9100	None; not relevant

Recognition: Forbes Asia "Best Under A Billion" 2023, 2024, 2025. Disruptions: H1 FY26 lost 15–20 days to North India rains plus ~12 days of Mexico/Colombia audits; billing paused 5–7 days for the Sep-25 GST change.

Segment Analysis

Ind AS 108 reports a single segment. All vertical figures below are management disclosures from decks and calls, not audited. [Fact]

Revenue by vertical (₹ Cr)

Vertical	FY24	FY25	YoY	FY26	YoY	Q1 FY26	Q1 FY27	YoY
Branded oncology	82.2	103.0	+25.3%	123.2	+19.6%	22.4	33.0	+47.3%
Derma / cosmetology	6.8	12.3	+80.9%	16.6	+35.0%	4.8	4.5	−6.3%
IVF (Nivian; Q1 FY27 only)	(21.0)	(35.0)	—	(43.0)	—	—	15.1	+45%*
CMO / CDMO	140.0	147.5	+5.4%	149.4	+1.3%	33.7	47.4	+40.7%
API (external)	20.7	20.1	−2.9%	24.8	+23.4%	7.1	8.3	+16.9%
Exports	46.0	79.5	+72.7%	70.9	−10.8%	32.3	17.2	−46.7%
Consolidated revenue from operations	295.7	362.4	+22.5%	384.8	+6.2%	100.2	125.5	+25.2%

*IVF growth is on Nivian's own pre-acquisition base. Q1 FY27 organic growth ~10.2% [Est.]. H1 FY26 (Nov-25 call): branded ₹60 Cr (+20%), CDMO ₹79 Cr (+8%), exports ₹43.2 Cr (+10%), API ₹12.25 Cr (+14%), derma ₹9.25 Cr (+45%); total ₹204 Cr (+13%). FY21 mix: CMO 50%, branded 28%, exports 16%, other 6%.

Vertical EBITDA (management bands)

Vertical	FY25 margin	FY25 implied ₹ Cr [Est.]	FY26 margin	FY26 implied ₹ Cr [Est.]
Branded oncology	34–35%	35–36	35–36%	43–44
CMO	15–16%	22–24	16–18%	25–27
Exports	27–30%	21–24	20–21%	14–15
API	19–20%	~4	~21%	~5
Derma	loss (GM 65–67%)	−3.1	breakeven (GM 57–58%)	~0
IVF (Nivian standalone)	—	—	18–19%	~8 (not consolidated)
Reported consolidated EBITDA ex-OI	20.58%	74.6	19.67%	75.7

The bands add up to ~₹87–91 Cr in FY26 against ₹75.7 Cr reported, so they are before unallocated costs or include other income. Use them to rank verticals, not to sum. The AR gives oncology EBITDA ex-derma of 20.6% for FY26 (FY25 24.03% on management's basis including other income).

Legal entities, FY26 (AR)

Entity	Revenue ₹ Cr	PAT ₹ Cr	% cons. PAT	% net assets	Role
BDL standalone	225.4 (+2.4%); total income 236.6	14.3	34.6%	61.1%	Export plant; regulated-market filing and BE costs
Adley Formulations	140.9 (+11.8%)	16.7	41.0%	23.8%	Domestic branded and CMO
Adley Lab	80.0 (+26.6%)	10.5	22.7%	16.4%	API; 69% intra-group
Beta Research	nil	nil	0%	0.004%	Dormant
Eliminations	~−61 [Est.]	—	—	−1.24%
Consolidated	384.8	41.5	100%	₹244.8 Cr

Standalone BDL (Brickwork)	FY24	FY25	FY26
Revenue ₹ Cr	197.6	220.2	225.4
EBITDA ₹ Cr	33.5	31.4	28.5
EBITDA margin	17.0%	14.3%	12.7%
PAT ₹ Cr	21.9	15.4	14.3
Interest cover	—	5.38x	2.54x

Fastest grower, laggard, platin economics, management focus

Vertical	Assessment	Management guide
Branded oncology	Fastest at scale: ~22% CAGR FY24–26 and +47% in Q1 FY27, at the highest margin (35–36%)	20–25% a year; 36% → 51% of mix by FY30; 20–25 launches over 3–4 years
Derma	~56% CAGR FY24–26 from a small base; −6% in Q1 FY27	+30–40% a year (~50% in FY27); >₹50 Cr in 3 years; 12–14% EBITDA at ₹50–60 Cr
IVF	+45% (Q1, own base)	+30%
Exports	Under pressure: −10.8% FY26, −47% Q1 FY27; margin band 27–30% → 20–21%; ₹20–25 Cr of tenders slipped	₹105–110 Cr FY27 (+50%); ₹200–250 Cr FY28; 30% of revenue by FY30
CDMO	+1.3% in FY26 after the platin exit, then +41% in Q1 FY27 (unexplained)	5–6% a year; 39% → 13% of mix
Platins	~₹30–35 Cr/yr, <7% of revenue, 10–15% gross contribution vs 50–70% elsewhere. Carboplatin ceiling ~₹2,850 vs input cost ~₹2,300–2,400, leaving no room for ~20% retailer + ~10% wholesaler margin. Platin sales were ₹46.5 Cr in FY25 and ₹31.6 Cr in 9M FY26, with nil in Q4. Domestic supply stopped in H2 FY26.	NPPA raised the ceilings 50% on 11 Jun 2026; management guides higher platin realisations in FY27

Financials: P&L

Five-year consolidated P&L (₹ Cr, audited)

₹ Cr	FY22	FY23	FY24	FY25	FY26	TTM Jun-26
Revenue from operations	183.84	227.11	295.71	362.36	384.83	410.16
YoY	~58%	23.5%	30.2%	22.5%	6.2%	—
Materials (net of inventory change)	94.46	105.69	149.41	171.35	171.18	—
Gross profit	89.38	121.42	146.30	191.01	213.65	—
Gross margin	48.6%	53.5%	49.5%	52.7%	55.5%	—
EBITDA (ex-OI)	42.70	53.12	59.99	74.61	75.67	83.31
EBITDA margin	23.2%	23.4%	20.3%	20.6%	19.7%	20.3%
Other income	0.76	0.75	1.36	6.44	11.18 (interest 9.86)	9.77
D&A	7.25	10.41	9.78	12.51	17.15	17.78
EBIT (incl. OI, pre-exceptional)	36.20	43.47	51.57	68.53	69.70	75.30
EBIT margin	19.7%	19.1%	17.4%	18.9%	18.1%	18.4%
Finance cost	1.90	2.41	2.82	6.99 (CCD 3.16)	15.31 (CCD 9.36)	14.54
Exceptional	0	0	0	−4.57 (pref-issue fees)	0	0
PBT	34.30	41.06	48.75	56.97	54.39	60.76
PBT margin	18.7%	18.1%	16.5%	15.7%	14.1%	14.8%
Tax	9.48	10.34	12.32	14.55	12.91	14.47
PAT	24.83	30.72	36.44	42.42	41.48	46.28 (owners 45.60)
PAT margin	13.5%	13.5%	12.3%	11.7%	10.8%	11.3%
EPS (₹)	25.82	31.95	37.90	42.02	40.92 (−2.6%)	~41.0
Adj. PAT (ex-CCD interest and exceptional, post-tax) [Est.]	24.8	30.7	36.4	~48.2	~48.5 (company: 48)	~51.6

Quarterly results (consolidated; quarterly reporting began Q3 FY25)

₹ Cr	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Revenue	88.28	93.76	100.21	103.38	87.27	93.96	125.55
YoY	n.a.	n.a.	n.a.	n.a.	−1.1%	+0.2%	+25.3%
QoQ	n.a.	+6.2%	+6.9%	+3.2%	−15.6%	+7.7%	+33.6%
Gross margin	52.1%	53.1%	50.4%	52.3%	58.7%	61.6%	56.6%
EBITDA ex-OI	18.45	17.35	19.71	21.29	16.99	17.67	27.36
EBITDA margin	20.9%	18.5%	19.7%	20.6%	19.5%	18.8%	21.8%
EBITDA YoY / QoQ	—	— / −6.0%	— / +13.6%	— / +8.0%	−7.9% / −20.2%	+1.8% / +4.0%	+38.8% / +54.8%
Finance cost	1.88	3.29	3.32	3.61	4.43	3.94	2.56
Exceptional	−2.35	−2.22	0	0	0	0	0
PAT	8.95	9.03	11.70	12.22	8.52	9.05	16.49 (own. 15.80)
PAT YoY	—	—	—	—	−4.8%	+0.2%	+40.9% / own. +35.0%
PAT QoQ	—	+0.9%	+29.6%	+4.4%	−30.3%	+6.2%	+82.2%
EPS (₹)	9.31	9.40	11.59	12.10	8.40	8.93	14.78 (+27.5%)

H1 FY25 (as a block): revenue ₹180.31 Cr, EBITDA ~₹38.8 Cr, PAT ₹24.43 Cr. H1 FY26 vs H1 FY25: revenue +12.9% (₹203.6 Cr), PAT −2.1%. Q3 FY26: total income ₹89.58 Cr; management EBITDA ₹19.28 Cr (~22%). Q2 FY27 not reported as of 13 Oct 2026.

Definition reconciliation: audited vs management

Metric FY26	Audited (used here)	Management / deck	Difference
Revenue	₹384.83 Cr (+6.2%)	₹396 Cr "net revenue" (vs ₹368 Cr)	Other income ₹11.18 Cr included
EBITDA	₹75.67 Cr / 19.67%	₹86.85 Cr / 22.57% (FY25 ₹76.97 Cr / 21.10%)	Includes other income
FY25 EBITDA	₹74.61 Cr / 20.58%	₹81.04 Cr / 22.37%; ₹84.12 Cr / 24.03% ex-cosmetology	Other income and derma excluded
H1 FY26 PAT	₹23.9 Cr (−2%)	₹28.71 Cr ex-CCD interest (+18%)	CCD coupon excluded
FY25 PAT	₹42.42 Cr	₹45.83 Cr ex pref-issue cost; CRISIL adj. ₹39.97 Cr	Exceptional item / CRISIL adjustments
Q1 FY27 PAT	₹16.49 Cr total	₹15.80 Cr owners	Nivian NCI ₹0.7 Cr

Q1 FY27 bridge and organic growth

Item	₹ Cr	Note
Q1 FY26 revenue	100.2
+ Nivian (new)	15.1	Acquisition
+ Organic change	10.2	Branded +10.6, CMO +13.7, API +1.2, derma −0.3, exports −15.1
Q1 FY27 revenue	125.5	+25.2%; organic ~10.2% [Est.]; market.md ~14% [Est., method not disclosed]
EBITDA ex-Nivian	24.5	+24.5% YoY
Other income	1.5 vs 2.9	Lower after the deposits were used
CCD interest	0.75 vs 2.10	Converted 25 May 2026

Earnings quality. FY26 PAT included ~₹9.9 Cr of FD interest earned on CCD money (~24–26% of PAT) and ₹9.36 Cr of CCD coupon; the two roughly cancel. The Q1 FY27 profit increase was operational: EBITDA ex-OI rose ~₹7.7 Cr, the finance-cost saving (~₹0.7 Cr) was more than offset by lower other income (~−₹1.4 Cr), and the result was +41%. The FY26 "extraordinary expenses" were never itemised beyond CCD interest. The consolidated P&L carries ₹1.15 Cr (FY25 ₹0.69 Cr) of "interest on loan (holding company)", which looks like intercompany interest that was not eliminated. Subsidiaries (55% of Q1 FY27 revenue) were not reviewed by their auditors in the quarterly results. Employee cost rose 31% in FY25 and 21% in Q3 FY26 (regulatory/QA hires). D&A went from ₹12.5 Cr to ₹17.2 Cr. [Fact]

Balance Sheet, Cash Flow & Ratios

Five-year balance sheet (31 March, ₹ Cr)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Net PPE	50.67	58.09	59.20	80.36	115.37
of which land	n.a.	n.a.	1.95	15.09	40.95 (35% of PPE)
Intangibles (goodwill on Adley ₹2.75 Cr)	4.29	4.66	5.39	8.57	9.90
CWIP	0	0	0	0	0
Inventory	22.48	30.62	49.81	59.77	74.46
Receivables	45.18	62.72	79.24	102.58	119.13
Receivables >6 months	n.a.	n.a.	7.30	25.47 (25%)	13.25 (11%)
Cash and bank (incl. FDs)	17.32	19.16	28.63	147.02	124.85
Trade payables	31.95	40.24	59.27	71.25	80.63
Total debt (reported)	~21	~20	14.71	138.05	147.81
of which CCD	0	0	0	117.00	110.00
Bank debt ex-CCD	~21	~20	14.71	21.05	37.81
Net worth (reported)	92.34	122.88	157.12	197.10	244.77
Net worth incl. CCD	92.3	122.9	157.1	314.1	354.8
Total assets	157.85	198.42	254.10	436.23	495.80

Equity after conversion [Est.]: 244.77 + CCD 110.0 + Nivian swap 48.58 + Q1 owners' PAT 15.80 ≈ ₹419 Cr (~₹377/share). Nivian NCI and goodwill come on top (PPA not yet disclosed). Accrued unpaid CCD interest of ₹2.73 Cr (FY25 ₹2.84 Cr) is a cash outflow due on conversion. Advances to suppliers rose from ₹5.4 Cr to ₹14.7 Cr; customer advances fell from ₹10.9 Cr to ₹1.1 Cr; raw-material stock rose from ₹15.3 Cr to ₹26.0 Cr.

Cash flow and FCF (₹ Cr)

₹ Cr	FY22	FY23	FY24	FY25	FY26	5-yr
Operating profit before WC	39.40	43.08	44.51	55.17	64.27	246.4
Change in WC	−9.77	−19.69	−13.58	−19.03	−26.99	−89.1
OCF	29.63	23.38	30.93	36.14	37.29	157.4
Capex	−19.43	−18.21	−11.62	−36.86 (land 13.1)	−53.48 (land 25.9)	−139.6
FCF	10.20	5.17	19.31	−0.72	−16.19	17.8
CFI / CFF	−21.75 / −0.97	−19.07 / −2.47	−13.97 / −7.49	−35.72 / +117.94	−51.39 / −8.07	—
PAT	24.83	30.72	36.44	42.42	41.48	175.9
OCF / PAT	1.19x	0.76x	0.85x	0.85x	0.90x	0.89x
OCF / EBITDA	0.69x	0.44x	0.52x	0.48x	0.49x	0.52x
FCF yield (FY-end mcap)	—	0.9%	1.6%	0.0%	−1.1%	now −0.9%

Profit vs cash. Over FY22–26 receivables rose ~₹74 Cr and inventory ~₹52 Cr, outpacing payables. FD interest (~₹9.9 Cr) sits in CFI while CCD coupon was partly accrued and unpaid. Like-for-like FY26 OCF is ~0.80x operating PAT. Excluding land, FY26 FCF was ~+₹9.7 Cr. H1 FY26 OCF was ~−₹37 Cr (call). Non-cash items (bonus shares, CCD-conversion premium) appear as financing inflows in the cash-flow statements. FY26 capex ₹53.5 Cr (management says ~₹45 Cr). Forward capex: ~₹25 Cr KSM plant (₹10.45 Cr spent in FY26) and ≤₹25 Cr over two years.

Working capital days

Days (year-end)	FY22	FY23	FY24	FY25	FY26
Debtor days	90	101	98	103	113
Inventory days (COGS)	87	106	122	127	159
Creditor days (COGS)	123	139	145	152	172
Cash conversion cycle	53	68	75	79	100
Inventory days (revenue)	45	49	61	60	71

Other measures: fact sheet FY26 debtor 105 / inventory 143 / WC 215 days. CRISIL gross current assets 260–280 days (216 in FY19), inventory 75–80 days, receivables ~100 days; a WC stretch is a CRISIL downgrade trigger.

Ratios

Ratio	FY22	FY23	FY24	FY25	FY26
RoE (avg equity, reported), primary	30.8%	28.5%	26.0%	24.0%	18.8%
RoE (CCD as equity)	—	—	—	18.0%	12.4% (14.4% adj. PAT)
RoCE (EBIT / avg capital employed)	37.1%	35.1%	33.2%	27.0%	19.2% (30.6% ex-cash)
D/E reported	0.18–0.23	0.13–0.16	0.09	0.70	0.60 (AR 0.63)
D/E (CCD as equity)	same	same	0.09	0.07	0.11
Net cash ex-CCD (₹ Cr)	~0	~0	13.9	126.0	87.0
Interest cover (EBIT/interest)	19.1x	18.0x	18.3x	9.8x	4.6x (AR 4.55x; BWR ISCR 4.94x)
Interest cover ex-CCD	19.1x	18.0x	18.3x	17.9x	11.7x (Q1 FY27 9.6x)
Current ratio	1.96	2.03	2.10	3.22	3.10
Asset turnover	1.33x	1.28x	1.31x	1.05x	0.83x
Fixed-asset turnover	3.4x	3.6x	4.6x	4.1x	3.1x

FY26 RoE variants: 18.8% (reported, primary); 19.6% (market.md, PAT ÷ average tangible net worth ₹211.7 Cr); 16.9% (company); 12.4% (CCD as equity). FY25 AR: RoE 21.5%, RoCE 19%, ICR 9.15, DSCR 6.90. Brickwork FY26: DSCR 3.58x. Tangible net worth (BWR) ₹151.7 Cr / ₹188.5 Cr / ₹234.9 Cr for FY24–26.

Debt structure and lenders (Mar-26)

Facility	₹ Cr	Terms
HDFC term loan	7.77	Matures Mar-2027 (CRISIL)
ICICI (incl. LAP)	7.39
SIDBI	6.95	Matures Feb-2027; personal guarantees from Neeraj, Rahul and Varun Batra
Axis	3.54
UCO	2.87	₹7.5 Cr sanction, 9.13%, 60 months; mortgage of Panchkula Plot 38
Vehicle loans (BMW Financial, Federal, HDFC, ICICI, Tata Motors Finance)	~1.6
Term loans total (current portion 6.77)	30.09
HDFC CC (Adley Lab)	2.78	Working capital
ICICI CC / OD	2.08 / 2.86	Working capital
Bank debt	37.81	Plus CCD ₹110.0 Cr (converted 25 May 2026)

Brickwork-rated facilities (6 Jul 2026), ₹42.89 Cr	₹ Cr
HDFC CC (long-term)	15.00
Term loans (SIDBI; ICICI LAP 6.74; UCO 2.61; HDFC IFG)	15.08
SIDBI WCTL / FCTL	0.33 / 1.48
HDFC pre-shipment credit (ST)	5.00
Pre-settlement risk (ST)	1.00
Performance BG (non-fund)	5.00

Limit utilisation ~16% (Brickwork) / ~33% (CRISIL). CPLTD FY27 ~₹6.8 Cr vs NCA ~₹58.6 Cr. Security: mortgages on Baddi (Nandpur), Panchkula and Derabassi plots plus hypothecation. Corporate guarantees to subsidiaries ₹24.91 Cr (ICICI-AFPL ₹13.01 Cr, HDFC-Adley Lab ₹11.50 Cr, SIDBI-Adley Lab ₹0.40 Cr); loans to subsidiaries ₹15.98 Cr. No NCDs or CP. Post-conversion bank rates ~7.5–8%; FY27 plan: WC loans ~₹7–10 Cr and term loans ~₹20 Cr. CARO: "previously sanctioned WC limits of ₹15 Cr". No FX hedging in FY26.

Credit-rating history

Date	Agency	Action
17 Jun 2020	Brickwork	"Issuer Not Cooperating" (monitoring information not furnished); company moved to CRISIL
24 Feb 2022	CRISIL	BBB/Stable
28 Feb 2023	CRISIL	Upgraded to BBB+/Stable
Jan 2024	Brickwork	BWR B+ INC
6 May 2024	CRISIL	BBB+/Positive
Apr 2025	Brickwork	BWR B INC
4 Aug 2025	CRISIL	BBB+/Positive reaffirmed
20 Jan 2026	CRISIL	BBB+/Positive reaffirmed on ₹8 Cr (HDFC CC 5, SIDBI TL 1.3, HDFC TL 1.7). CCDs treated as equity. Upgrade trigger: revenue >₹400 Cr at healthy margins. Downgrade: OPM <17%, WC stretch, debt-funded capex/M&A
6 Jul 2026	Brickwork	Old ₹7.25 Cr INC ratings withdrawn; BWR A-/Stable, A2 assigned on ₹42.89 Cr (one notch above CRISIL); ESG "Adequate"
5 Sep 2026	FY26 AR (CG report)	Lists only Brickwork A-/A2 as "No change"; CRISIL omitted. Brickwork's SEBI status unverified [UNVERIFIED]
25 Sep 2026	CRISIL	Advisory: "awaiting adequate information"; not a reaffirmation

₹117 Cr CCD: terms and use of proceeds

Allotted 27 Nov 2024: 7,07,651 unsecured CCDs at ₹1,653.40 (₹117,00,30,163.40) plus 70 equity shares. Coupon 0.65%/month (7.8% p.a.); 1:1 conversion; 18-month tenor to 26 May 2026. Holders: HealthQuad Fund II (lead), Inti Capital VCC – Inti Capital I (Singapore), Generational Capital Breakout Fund 1; Tanas Capital co-led; O3 Capital advised. FY25 interest ₹3.16 Cr was unpaid (CARO); FY26 ₹9.36 Cr. Issue expenses ₹4.57 Cr went to the P&L (consultancy ₹3.03 Cr to unnamed consultants, commercial DD ₹0.50 Cr, financial/tax DD ₹0.42 Cr, legal DD ₹0.27 Cr, secretarial ₹0.30 Cr, valuation ₹0.06 Cr). Management had said in Nov 2024: "we don't need any funds till ₹450–500 crores of turnover."

Object (₹ Cr)	Proposed	Used by 31 Mar 26	Unused
Facility upgrade – Adley Formulations	8	2.25	5.75
Facility upgrade – Adley Lab	5	1.35	3.65
R&D facility (new; land since dropped)	15	0.95	14.05
Geographical expansion	10	0	10
Capex – new manufacturing setup	44	9.52	34.48
Capital investment incl. acquisitions (Nivian cash ₹20.82 Cr likely, Apr-26)	20	0	20
General corporate purposes	15	9.80	5.20
Total ("no deviation"; monitoring agency Brickwork)	117	23.87	93.13

Share-count and dilution history

Date	Event	Shares	Price ₹	Shares after
Oct 2017	IPO, NSE Emerge (22.96 lakh shares at ₹85, ~₹19.5 Cr; Pantomath)	22,96,000	85	86,31,500
FY20	Unexplained allotment (~11%; promoters gained ~4.7 lakh), coinciding with the Adley Lab acquisition [UNVERIFIED]	~9,82,290	n.d.	96,13,790
27 Nov 2024	Preferential: 70 equity shares + 7,07,651 CCDs	70	1,653.40	96,13,860
27 Mar 2025	Bonus 1:20 (5,16,076 approved; 35,383 reserved for CCD holders)	4,80,693	—	1,00,94,553
24 Nov 2025	Main Board migration	—	—	1,00,94,553
29 Nov 2025	CCD conversion (Generational Capital, ₹7.0 Cr)	42,337	1,653.40	1,01,36,890
4 Feb 2026	EGM: Nivian swap, ESOP 2026, authorised capital ₹11.0 Cr → ₹11.4 Cr	—	—	—
25 Apr 2026	Nivian swap (33 allottees)	2,83,668	1,712.49	1,04,20,558
25 May 2026	Remaining CCD conversion (₹110 Cr)	6,65,314	1,653.40	1,10,85,872
Aug 2026 (board 18 Aug)	Bonus true-up to CCD holders	35,383	—	1,11,21,255

Net dilution +10.2% vs Mar-25 (+9.8% on listed shares only). ESOP 2026: up to 2,00,000 options (~1.8%), exercise price at NRC discretion, 1–5 year vesting; no grants yet (merchant banker and NSE approval pending). No warrants or QIP.

Balance-sheet risks: land is 35% of net PPE, and a ₹16.09 Cr FY26 land purchase has no disclosed seller and is not shown as an RPT; the WC stretch; ₹24.9 Cr of subsidiary guarantees missing from the contingent-liability note; Nivian PPA/goodwill still to come; supply overhang from ~6.7% PE-held shares and ~2.6% Nivian swap shares.

Management, Promoters & Governance

Overall: moderate-to-elevated governance risk. No SEBI or MCA orders, no pledge, and unmodified audit opinions. Against that, the issues below accumulate. governance_ar.md (primary AR text) takes precedence where it conflicts with governance.md.

Promoters

Person	Role / holding	Background
Late Vijay Kumar Batra (DIN 01083215)	Founder; CMD until his death on 23 Jan 2021	Founded Adley Group in 1985; ran the Adley Formulations proprietorship (oncology from 2008), moved into Beta in 2018. Bought 50,400 shares at ₹84.95 on 1 Sep 2020
Mrs Neeraj Batra (DIN 02229217)	64,73,631 shares: 63.86% (Mar-26) / 58.40% (Jun-26); non-exec director until 2019	Age ~68; director of Kedge Pharmacia. Relationship to the MDs is not stated in either AR (inferred: the founder's widow and the brothers' mother) [Inferred]. Not listed as a related party despite being the controlling holder and a personal loan guarantor. Sold 1,85,115 shares on 13 Nov 2025
Rahul Batra (DIN 02229234)	CMD (MD since 27 Jan 2021); 41,632 shares (0.41% / 0.38%)	MSc Business & Management, Strathclyde. Heads sales and marketing; with the company since ~2014. Bought 2,400 shares on 20 Jan 2023. Directorships: AFPL, Adley Lab, BT Associates, Beta Research (plus Adley Lifesciences, Adley Resorts and Kedge per MarketScreener; not in the AR)
Varun Batra (DIN 02148383)	Jt MD (also titled MD in the AR); 34,891 shares (0.34% / 0.31%)	Business degree (Toronto); EMBA Symbiosis; heads production and exports. Brother of Rahul (AR p.46)
Aditi Batra, Heena Batra	619 shares each (0.01%)	Relationship not stated (possibly spouses) [Inferred]

Promoter-group private companies outside the listed entity: Adley Lifesciences Pvt Ltd (pharma), Kedge Pharmacia India Pvt Ltd (specialty chemicals), Adley Resorts Pvt Ltd, BT Associates Pvt Ltd (landlord). None of the first three is named in either AR. Rishi Herbal Products, a partnership firm of the directors, supplies AFPL.

Key management and remuneration (FY26)

Name	Role	From Beta ₹	From AFPL ₹	Total ₹	Note
Rahul Batra	CMD	1,51,00,000	1,51,00,000	3,02,00,000	49.05x median (Beta only); cap ₹50 lakh/month (Beta), ₹1 Cr/month (AFPL)
Varun Batra	Jt MD	1,51,00,000	1,51,00,000	3,02,00,000	Same terms; reappointed 27 Jan 2026 – 26 Jan 2031
Ashutosh Shukla	WTD, sales & marketing	45,98,031	—	45,98,031	−2.31%; RPT note ₹47.12 lakh incl. rent ₹7,000/month; reappointed 20 Jan 2027 – 19 Jan 2032 at ₹3.94 lakh/month (cap ₹10 lakh)
Balwant Singh (DIN 01089968)	WTD, Baddi plants	32,86,560	—	32,86,560	+0.76%; to 4 Aug 2029; PG Dip HR (DAV Chandigarh)
Ram Chander Jha	AFPL director	—	16,96,172	16,96,172	AFPL director-salary line ₹316.61 lakh
Nipun Arora	CFO (CA, ACS, ICWA)	32,03,256	—	32,03,256	−16.09%
Rajni Brar	CS (ACS 24684)	12,17,645	—	12,17,645	+23.01%; CS since ≤2018
Group ED pay		3.81 Cr	3.02 Cr	~6.8 Cr	≈16% of consolidated PAT; Beta-paid = ~27% of standalone PAT

Median employee pay ₹3,07,829 (+32.72%); non-managerial pay +10.85%, managerial −0.67%. Independent directors get only ₹3,000 per meeting. Senior management: VP QA Kalpesh Dhodi; GM Purchase Seema Chopra; GM Sales (API) Jayant Kumar; GM International Shishir Tiwary and Shailendra Sharma. Seema Chopra resigned as WTD on 5 Feb 2025. The FY26 AGM notice (Annexure 1) concedes that pay "exceeds the ceiling prescribed" under Schedule V. Special resolutions: 20th AGM (30 Sep 2025, MD reappointments) and 19th AGM (30 Sep 2024, pay revisions). The FY25 notice has drafting errors (calls them ordinary resolutions; gives the tenure as 2027–32).

Board of directors and FY26 attendance (16 meetings)

Name (DIN)	Role	Appointed	Attended	AGM	Background
Rahul Batra (02229234)	CMD, promoter	01/08/2014	16	Yes	See above
Varun Batra (02148383)	Jt MD, promoter	01/08/2014	16	Yes	See above
Balwant Singh (01089968)	WTD	01/08/2014	16	Yes	HR/IR; ~19 yrs pharma
Ashutosh Shukla	WTD	20/01/2022	16	Yes	EMBA Symbiosis; 20+ yrs pharma sales
Ajay Mahipal (06949940)	Non-exec, HealthQuad nominee	27/11/2024	6	No	CA, SRCC, IIM MBA; ex-CURRAE, Patni Family Office, EY, AmEx, Elara, Pepsi
Rohit Parti (07889944)	ID	26/07/2017	16	Yes	MBBS, cardiologist; term ends 25 Jul 2027
Manmohan Khanna (07888319)	ID	26/07/2017	16	Yes	Architect; IIA chapter chair; term ends 25 Jul 2027
Sanjay Sehgal (01235531)	ID	27/11/2024	7	Yes	M.Com; ~30 yrs finance/logistics
Lalit Kumar Watts (10906518)	ID	05/02/2025	5	No	IIM-C MBA; 35 yrs HR (BPCL)
Dr Monica Jain (05253864)	ID (woman)	05/02/2025	12	Yes	MS Ophthalmology. An aggregator flagged her DIN as deactivated; the PCS certificate says she was not disqualified at 31 Mar 2026

10 directors: 4 executive, 1 nominee, 5 independent (exactly 50%, the Reg 17 minimum with an executive chair). FY25 secretarial audit: one-ID shortfall under s.149(4) and NRC composition breach until 26 Nov 2024; FC-GPR for the bonus not filed with RBI. FY26 secretarial audit: ROC filing delays and 35,383 bonus shares un-allotted, yet the DR says "no qualifications". No risk-management policy ("not applicable"). The 21st AGM (30 Sep 2026) passed all 6 resolutions with 100% in favour (60,75,165 votes; institutions 2,37,035).

Shareholding trend (%)

Quarter	Promoter	FII	DII	Public	Holders	Shares
Mar-25	66.73	0.90	0.17	32.20	3,054	1,00,94,553
Jun-25	66.73	0.90	0.26	32.11	3,139	1,00,94,553
Sep-25	66.73	0.90	0.29	32.07	3,184	1,00,94,553
Dec-25	64.90	1.14	1.90	32.07	3,694	1,01,36,890
Mar-26	64.63	1.16	2.15	32.06	4,736	1,01,36,890
Jun-26	59.10	1.02	6.23	33.65	7,359	1,10,85,872

Promoter reconciliation	Promoter shares	Denominator	%	Driver
Mar-25 (AR)	67,36,507	1,00,94,553	66.73	Neeraj 66,58,746 (65.96%)
Dec-25	65,51,392	1,00,94,553	64.90	Sale of 1,85,115 (13 Nov 2025 bulk deal at ₹1,686)
Mar-26 (AR)	65,51,392	1,01,36,890	64.63	42,337 CCD conversion counted (dilution)
Jun-26	65,51,392	1,10,85,872	59.10	CCD 6,65,314 + Nivian 2,83,668 (dilution)
After true-up	65,51,392	1,11,21,255	~58.9	35,383 bonus true-up

The sale (~1.8% of capital) is below the SAST Reg 29(2) 2% trigger; the PIT Reg 7(2) filing was not retrieved. Earlier inputs differ: narrative.md and governance.md called it unconfirmed and split it ~1.57 lakh (Dec) + ~27,000 (Mar). The share-count arithmetic above supersedes that. An insider database row shows 31,051 shares with a value of ~₹31.2 Cr, which is internally inconsistent. Pledge: nil (current and historical). Angel One/Tradebrains cite an interim "May-26" pattern of FII 2.95% / DII 6.01%, which conflicts with Jun-26 (unreconciled).

Named holders (Jun-26)

Holder	Category	%	Entry / note
Mrs Neeraj Batra	Promoter	58.40	Sold ~₹31 Cr at ₹1,686 (Nov-25)
Suryavanshi Commotrade Pvt Ltd	Body corporate	6.13	680,026 shares; Kacholia-linked per heard.md/Trendlyne [Inferred]; not in the AR's >5% table (Mar-26 "other bodies corporate" 8.56% across 57 holders)
Ashish Kacholia	Public	4.91	543,800 shares; first bought Mar 2019; combined 10.1% (Mar-20), 11.6% (Jun-21), 12.5% (Mar-26); ~11.0% now ≈ ₹206 Cr. Sold ~39,000 shares in Q1 FY27 (governance.md) vs dilution only (heard.md): contested
HealthQuad Trust II	AIF	4.09	CCD conversion at ₹1,653.40 (~₹1,575 bonus-adjusted)
Inti Capital VCC – Inti Capital I (Singapore)	Non-institution/FPI (classification unclear)	1.91	CCD conversion
Airavat Capital Trust II (Cat-III AIF)	AIF	1.60	Bought 1,55,925 at ₹1,686 on 13 Nov 2025 from the promoter block (1.54% → 1.68% → 1.60%)
Bsas Infotech Ltd	Public	1.20	First seen Mar-26 at 1.31%
Generational Capital Breakout Fund 1	Fund	<1	42,337 shares from conversion
Nivian sellers (33; e.g. Anjali Ajit Deval 1.26 lakh)	Public	~2.6	Swap at ₹1,712.49; 6-month ICDR lock-in likely ends ~Oct-26 to early 2027 [UNVERIFIED]
Mutual funds / insurers	—	nil	Small-holder retail (<₹2 lakh) 12.84%; ~78% in strong hands

Bulk / block deals

Date	Party	Side	Qty	₹
13 Nov 2025	Neeraj Batra (promoter)	Sell	1,85,115	1,686 (~₹31.2 Cr)
13 Nov 2025	Airavat Capital Trust II	Buy	1,55,925	1,686 (~₹26.3 Cr)
1 Sep 2020	Vijay Kumar Batra	Buy	50,400	84.95
24 Jul 2020	Onkar Singh	Buy	87,200	96.03
24 Jul 2020	Adesh Ventures LLP	Sell	1,08,000	95.52

No bulk or block deals during the Apr–Oct 2026 rally or sell-off.

Related-party transactions (FY26 AR, ₹)

Entity	Counterparty	Nature	FY26	FY25
Beta	Adley Lab	Purchase of goods	26,01,40,601	21,31,56,450
Beta	Adley Lab	Sale of fixed asset / interest received	19,75,000 / 65,73,914	— / 23,04,263
Beta	AFPL	Sales / purchases	1,82,95,878 / 4,41,94,309	1,28,82,028 / 2,60,03,714
Beta	AFPL	Interest received / sale of FA	49,65,432 / 26,64,606	45,54,309 / 1,67,498
Beta	BT Associates (common shareholders >50%)	Building rent	28,88,640	28,88,640
AFPL	Adley Lab	Purchase of goods	29,25,17,051	21,84,64,270
AFPL	Rishi Herbal Products (directors' partnership firm)	Purchase of goods	48,10,280	60,14,880
AFPL	Rahul Batra / Varun Batra	Salary incl. bonus	1,51,00,000 each	1,51,00,000 each
Beta	Ashutosh Shukla	Rent	84,000	84,000

Gaps: no outstanding balances, guarantees (₹24.91 Cr) or promoter personal guarantees in the RPT note; Neeraj Batra not listed. Adley Lab: ₹55.3 Cr of ₹80.2 Cr (69%) intra-group (FY25 ₹43.2 Cr), so its profit depends on transfer prices ("at ALP"). Loans to subsidiaries: Adley Lab ₹10,15,85,124; AFPL ₹5,81,66,827 (total ₹15,97,51,951; FY26 advances ₹7.89 Cr).

Auditors and audit quality

Role	Firm	Notes
Statutory (parent)	Khurana Sharma & Co, Chandigarh (FRN 010920N; partner CA Vibhor Khurana; 2 partners, 4 assistants, 8 articles)	First term 19th → 21st AGM (2024–26); second term to the 23rd AGM (2028) at ₹4.20 lakh p.a.. A 20 Jul 2022 board outcome on auditors suggests an earlier engagement, so tenure is unresolved
Statutory (subsidiaries)	Kalra Rai & Associates (FRN 008859N)	Appointed 30/09/2024 (AFPL) and 30/09/2025 (Adley Lab); audits ~65% of PAT
Secretarial	Dinesh Bhandari, PCS (FCS 5887)	FY25–FY30
Internal	Srivastava V.K. & Associates (FRN 028628N)	Sole-proprietor firm (est. 2015); fee ₹3.60 lakh
Cost	Charu Jindal & Co, Dehradun (FRN 103508)	Fee ₹1.25 lakh; total auditor fees ₹9.05 lakh (both years)

Audit finding	Detail
Opinion	Unmodified (FY25, FY26; standalone and consolidated); IFC unmodified; audit trail operated
Format	No Key Audit Matters, no "Basis for Opinion", no EoM in any of the four reports. Old pre-SA 700 (Revised) format. Rule 11(e)/(f) representations absent
Consolidated report	Refers to "its subsidiary" (singular); no Other Matter paragraph on reliance on other auditors; CARO 3(xxi) says "no qualifications", glossing over the advance-tax default
CARO vii(a)	Default in payment of advance tax (FY25 and FY26; also AFPL and Adley Lab)
CARO vii(b)	Disputed income tax ₹12,120 (AY20-21) and ₹92,10,890 (AY21-22; ₹72,51,730 in FY25), arising from s.133(6) third-party notices; under appeal
CARO vii(c) FY25	MSME payments delayed; s.16 interest of ₹13,698.91 not recognised; s.22 disclosures incomplete
CARO vi	Says cost records "not applicable", contradicting the DR (cost auditor appointed)
CARO x(b)	FY25: preferential issue complied; CCD interest of ₹3,15,97,314.78 unpaid. FY26: not reported
CARO i(c)	FY26: all title deeds in the company's name (no exception)
Profit mismatch	Reserves note profit ₹1,449.90 lakh vs reported PAT ₹1,433.45 lakh; ₹97.82 lakh (FY25 ₹241.68 lakh) debited directly to retained earnings as prior-period adjustments
Re-keyed subsidiary accounts	An editorial note in the AR (p.192); the promoter table still lists the late V.K. Batra
Quarterly reviews	Subsidiaries not reviewed (Q3 FY26); UDIN missing on Q1 FY27 limited review (NSE query; refiled 23 Jul 2026)

Contingent liabilities

Item	FY26 ₹	FY25 ₹
Standalone BGs (tender: AIIMS, RCC, state corporations, MoD)	2,14,08,262	1,67,81,793
Consolidated BGs	2,34,39,508	1,72,93,079
AFPL contingent liabilities	20,31,246	5,11,286
Disputed IT (AY21-22)	92,10,890	72,51,730
Corporate guarantees to subsidiaries (not in the CL note)	24,91,33,517	—
Capital commitments / claims not acknowledged	Nil	Nil

Subsidiaries and acquisitions

Entity	Stake	Beta's cost of investment	Net assets ₹ Cr	Acquired	Assessment
Adley Formulations (inc. 09/10/2018)	99.99%	₹1.26 Cr (subscription at par); the business purchase from the proprietorship is undisclosed	58.16	2018 (from the promoter's proprietorship)	Worked: ₹141 Cr revenue / ₹16.7 Cr PAT; related-party origin
Adley Lab (inc. 10/04/1992)	99.99%	₹4.50 Cr for 17,58,044 sh (~₹25.6/sh)	40.07	Oct 2019 (existing supplier)	Worked: ₹80 Cr / ₹10.5 Cr; possible FY20 promoter share swap [UNVERIFIED]
Beta Research	99.99%	₹1 lakh	~0	—	Dormant
Nivian Lifesciences	66.09%	₹69.40 Cr (10,94,535 sh at ₹634.03)	n.d.	Apr–May 2026	Unproven; ~25x EBITDA; no put/call for the 33.91%
Beta UBK International (Uzbekistan)	n.d. (forum: 60%)	Nil (written off)	—	2018	Failed plant

Nivian: announced 9 Jan 2026; EGM 4 Feb 2026; swap allotment 25 Apr; 64.26% transferred by 30 Apr, the rest 22 May. Valuer Hitesh Jhamb (8 Jan 2026). Other SHA parties: Ronak Manish Jain and Dattatraya Gopal Ranjane. 33 swap allottees include Anjali Ajit Deval, Kayadam Ramanathan Bharat, Neha Bagla, Gurvinder Singh, Roshan Thapa, Lalitha Natrajan Sanarnarayan, Deepak J Chokhani, Shruti Kanodia, Anisha Agarwal, Santosh Pandey, Sarla Devi Dogra, Neha Dipesh Jain, Dineshkumar L Dhanuka, Jajodia Equity Advisors Services, J M Global Equities, Narendra Himatsingka, Neha Goenka, Puja Goenka, Shweta Sethi, Sushma Himatsingka, Svastha Consulting LLP, Sandeep Raina, Charuben Yogesh Ajmera, Ketan Malkhan, Maruti Pujari, Simple M Prahladka, Kavita Kanodia, Suresh Kanodia, Atul Bapna, Manoj Sharma, Long Run Services LLP, Sheza Corporate Advisors LLP and Sweta Rathi (market.md says 28). Declared non-related. Filing inconsistencies: share counts don't reconcile, and a corrigendum was issued.

Land title (Barotiwala)

In FY25, AFPL's Kotla/Barotiwala land and main plant building, and the SCO-42 Panchkula showroom, stood in the name of "Adley Formulations (Prop. Sh. Vijay Kumar Batra)". CWP 7630/2021 was disposed of on 27 Jul 2022. A Revenue order of 11 Jan 2023 allowed mutation subject to stamp duty. CWP 1464/2023 challenged that, with an execution petition filed 10 Jul 2024 and the "outcome awaited". The stamp duty is unquantified and not in contingent liabilities. The FY26 AR dropped the disclosure, and AFPL's CARO now says title is in the company's name. Status: [UNVERIFIED — status not disclosed]

Governance checks

Check	Finding	Severity
SEBI / MCA orders	None found	Low
Exchange fines and queries	NSE ₹10,000 + GST (14 Nov 2024, XBRL one day late); queries Feb-25 (director affirmation) and Jul-26 (UDIN); volume-surge query ~15 Jun 2026	Low
Promoter selling	1,85,115 sh on 13 Nov 2025, before the guidance cut	High
Executive pay	~₹6.8 Cr group; half outside the s.197(12) table	High
Audit quality	₹4.2 lakh fee; no KAMs; split auditors; drafting errors	Medium-High
Rating disclosure	AR omits CRISIL; CRISIL awaiting information	Medium
Idle proceeds	₹93.13 Cr unused while paying a 7.8% coupon	Medium
Intra-group concentration	Adley Lab 69% intra-group; Rishi Herbal RP supplier	Medium
Land title	Disclosure dropped	Medium
Board	Local IDs, no pharma/audit depth; Watts 5/16, Mahipal 6/16; 2 IDs time out Jul-27	Medium
Open items	FY20 share issue; HealthQuad/Inti SHA rights (CG 10.18: no clause 5A agreements); BSE listing (aggregator code 535022; AR says NSE only); Suryavanshi identity; ₹16.09 Cr land seller	Open

Supply Chain

↑ Upstream: what Beta depends on

Input	Source	Dependence / risk	Pass-through
KSMs / N-2, N-3 intermediates	Mainly China (unnamed)	High and rising. Raw-material imports ₹27.65 Cr in FY26 (FY25 ₹19.85 Cr; FY24 ₹18.5 Cr), almost all at Adley Lab (₹27.62 Cr): ~14.9% of group purchases of ₹185.9 Cr and ~61% of Adley Lab's ₹45.3 Cr. Weak DMF support blocks EU filings	Mitigation: ~₹27 Cr intermediate plant by end-Q3 FY27
Oncology APIs	Captive Adley Lab: 70% (AR MD&A) / 65–70% / "80%+" (deck)	Medium; one API site feeds both plants; API prices volatile	Scheduled drugs: WPI-only (+0.65% Apr-26). CDMO negotiated. Tenders fixed price
Platinum-group APIs	External	Input cost exceeded the ceiling, so domestic platin supply was exited	Failed until the +50% ceiling revision (Jun-26)
Excipients, packing, solvents	Domestic; creditor accounts BDL 531, AFPL 338, Adley Lab 218	Fragmented. MSME dues BDL ₹0.89 Cr, AFPL ₹1.48 Cr, Adley Lab ₹1.64 Cr; ~5 months of solvent buffer	Partial
Derma finished goods	Promoitalia (Italy), Frezyderm (Greece)	Single-source exclusive licences; EUR exposure	Premium pricing; 65–70% gross contribution target
IVF finished goods	11 third-party CMOs	Fully outsourced	Scale synergies planned
Related-party supply	Rishi Herbal Products → AFPL	₹0.48 Cr FY26 / ₹0.60 Cr FY25	—
Imported capital goods and services	EU etc.	₹1.12 Cr capital goods; ₹5.24 Cr services (registrations and audits); FX outgo ₹8.3 Cr vs earnings ₹67.7 Cr	Unhedged

↓ Downstream: who depends on Beta

Channel	Customers	Stickiness / tenor
Domestic branded	Oncologists → stockists (₹5.7 Cr commission) → hospital pharmacies; 85%+ of corporate and government hospitals. Logos: HCG, Fortis, KIMS, Manipal, Max, Medanta, AIIMS, Amala, Amrita, Apollo, Aster DM, DMH, Jupiter, Kokilaben, MVR Cancer Centre, Paras, Ruby General, Shalby, Tata Medical Center, Yashoda	Prescription habit, formulary listing
Indian institutions / tenders	AIIMS New Delhi, Kalyani, Bilaspur; DGHS; DGAFMS; MoD; Dept of Pharmaceuticals; Chittaranjan National Cancer Institute; Regional Cancer Centre; Rajasthan RMSCL; Kerala KMSCL; Odisha OSMCL; Haryana HMSCL; Punjab Health Systems; J&K Medical Supplies; West Bengal DHS; BMC; Gujarat Cancer Research Institute; Tata Memorial	1–3 year rate contracts; BGs ₹2.34 Cr running to 2030
CMO	Glenmark, Intas, Alkem, Cadila/Zydus, Torrent, Eris, Hetero, Amneal, Reliance Life Sciences, Shilpa, Caplin Point, RPG Life Sciences; output sold under their brands	95% repeat; switching needs re-licensing and re-validation; tenors n.d.; clients are also competitors
Exports	Foreign government tenders and distributors; registrations held in Beta's name	Annual tenders (budget Jan–Dec; awards Dec–Mar; two instalments); registration takes 18–36 months per product per country
API	Indian formulators (~₹25 Cr; ~25 debtor accounts incl. 2 affiliates)	—
IVF	Fertility clinics, IVF chains, IUI centres, gynaecologists; corporate hospitals targeted	—

Concentration proxy	Value
Top-5 / top-10 customer share	Not disclosed (FY25/26 AR, CRISIL, decks); CRISIL: "diversified"
Debtor accounts FY26	BDL 180; AFPL 121; Adley Lab 25
Top-5 export countries	~30% of exports (≈5–6% of group revenue); one country ~₹13 Cr (~3.4%); a single tender delivers 1.2–1.4 mn units per instalment
CMO	39% of revenue across ~30 partners
Nivian	Top brand ~22%

Value-chain map

China KSM / intermediate vendors (unnamed; ₹27.6 Cr imports FY26)
      │  DMF-documentation risk
      ▼
[New intermediate plant, Derabassi — commissioning FY27]
      ▼
Adley Lab API, Derabassi (90 TPA; ₹80 Cr gross, ₹55 Cr captive)  ──► External API buyers (~₹25 Cr)
      │  70–80% of formulation API need
      ▼
Formulation: AFPL Barotiwala (domestic)  |  BDL Nandpur (export/regulated)
      ├──► CMO: Glenmark/Intas/Alkem/Cadila/Torrent → their brands → hospitals → patients (39%)
      ├──► Own "Adley" brands → stockists → corporate & govt hospitals, state tenders → oncologists (36%)
      ├──► Exports → govt tenders & distributors, ~40 countries (LATAM 42/APAC 32/Africa 19/MENA 7) (18%)
      └──► Derma (Promoitalia/Frezyderm) → dermatologists; IVF (Nivian, 11 CMOs) → fertility clinics

Where pricing power sits. Strongest: NDDS/first-to-market brands (Caxfila-OS, Adxate-OS, AB-Pacli) and branded TKIs sold to corporate hospitals (35–36% EBITDA), plus premium in-licensed aesthetics. Constrained: NPPA/DPCO-scheduled cytotoxics; the platin exit shows Beta has none under a ceiling. Weak: CMO (15–18% EBITDA; brand owners keep the margin) and L1 tender exports (27–30% → 20–21%). Upstream: Chinese KSM vendors have moderate leverage. New threat: the NPPA 30% trade-margin cap shifts power to hospital buyers that lose their spread. [Analyst View]

Competitive Position

Indian oncology market

Metric	Value	Source / note
Anti-cancer drug market (all channels)	~₹12,500 Cr/yr; ~225 drugs, ~500 formulations; scheduled (NLEM) ~₹2,250 Cr (18%)	NPPA/DoP via Medical Dialogues; trade/MRP value
Retail anti-neoplastics (Pharmarack)	~₹501 Cr/month (Feb-26), ~2% of IPM (~₹6,000 Cr/yr)	Misses hospital and tender sales
Recent growth	Feb-26 12.9%; Mar 12.4%; Apr 17.1%; Jun 16.7%; Jul 21.1% (fastest therapy); Sep 21.6% (volume 9%) vs IPM ~10% MAT	Pharmarack; CY26 base case 12–13%
Third-party estimates	US$2.88 bn (2025), 14.7% CAGR to 2032 (MarkNtel); +US$2.36 bn at 20% CAGR 2025–30 (Technavio); US$11.7 bn incl. services (IMARC)	Indicative
Cytotoxic market (management)	~₹3,000 Cr → ₹4,000–5,000 Cr by 2028–30	Nov-24 call
Disease burden	14.97 lakh cases (2023); 15.7 lakh projected (2025)	ICMR-NCRP
Beta's share	~1% on mixed bases; ~1.5–2% like-for-like [Est.]. Claims "top 10 branded oncology"; Vision 2030 "top five in cytotoxic oncology" (no IQVIA confirmation) [UNVERIFIED]

Structural trends: (1) Corporate hospitals capture large trade spreads, the target of the TMR and the Supreme Court case. (2) The market is shifting to targeted, IO and biosimilars; MNC top-5 ~18%; Beta has no biosimilar (NDA stage, 3–4 years away). (3) Patent cliffs open early-generic windows. (4) The oral shift (48% of Beta's branded sales) is highly exposed to the TMR. (5) Exports are L1 tenders; regulated markets need EU-GMP and BE. (6) CDMO: large firms outsource cytotoxics, and rivals are adding capacity (Shilpa +35%).

Policy and regulation

Policy	Status (13 Oct 2026)	Impact on Beta
NPPA 30%-of-MRP trade-margin cap, non-scheduled anti-cancer drugs (Para 19, DPCO 2013)	In-principle 8 Oct 2026 (151st meeting); ~110 drugs incl. 35 patented; DGHS list due 14 Oct; implementation expected late Oct; MRP cuts 20–70%; ~₹2,500 Cr/yr savings; average mark-up ~170%, up to 700%. 2019 precedent: 42 drugs, 526 brands, cuts up to 91% (~₹984 Cr/yr)	High It hits the hospital-channel branded generics channel. MRP resets to ≤PTD/0.7, but PTD is likely to be pressured and brands switched. Expect disruption in Q3 FY27. Beta's non-scheduled share is undisclosed [UNVERIFIED]. After the 2019 cap Beta still grew ~36% in FY20, when branded was ~25% of revenue
Supreme Court (Kishan Chand Jain; Justices Vikram Nath and Sandeep Mehta)	29 Sep 2026: called a 10x mark-up "carnage" and floated a uniform 16% margin; questioned captive hospital pharmacies. 12 Oct outcome not found	Medium-High tail risk
NLEM 2022 / DPCO	63 anti-cancer drugs in NLEM; 131 scheduled formulations under ceilings; WPI +0.65% from 1 Apr 2026	Medium
Carboplatin / cisplatin ceiling +50%	NPPA 147th meeting, 11 Jun 2026: carboplatin ₹90.74/ml; cisplatin ₹10.89/ml	Positive revives the ₹30–35 Cr platin line
GST cut on cancer drugs	Sep 2025	Neutral (5–7 day billing pause)
Customs exemptions	Budget 2024: 3 drugs; 2025: 36; 2026-27: 17 more cancer drugs at nil BCD	Slightly negative
Revised Schedule M	Large firms Jan-25; ≤₹250 Cr firms 31 Dec 2025; 1-yr extension mooted [UNVERIFIED]	Low risk; tailwind if small CMOs exit
UCPMP 2024	Non-statutory code	Low-Medium
Pharma PLI	Anti-cancer drugs believed eligible [UNVERIFIED]; Beta not a beneficiary	Peer cost edge

Listed peers (FY26 consolidated; market cap as of 13 Oct 2026)

Company	FY26 Rev ₹ Cr	YoY	EBITDA (%)	PAT (%)	RoE	P/E TTM	EV/EBITDA	Moat
Beta Drugs	384.8	+6.2%	75.7 (19.7%)	41.5 (10.8%)	18.8%	~41x	~22x	Narrow: integrated cytotoxic platform, hospital reach, NDDS
Natco Pharma	4,078	−7.9%	1,462 (35.9%)	1,418 (34.8%)	17.1%	13.5x	~12.4x	Wider: US first-to-file; Q1 FY27 revenue −43%; ~₹3,100 Cr investments
Shilpa Medicare	1,535	+19.8%	435 (28.3%)	243 (15.8%)	9.0%	~63.9x	~40.9x	Medium: oncology API DMFs, regulated formulations, CDMO, ADCs
Venus Remedies	766	+18.8%	147 (19.2%)	103 (13.4%)	15.6%	18.4x	~11.5x	Narrow: injectables; Saudi FDA plerixafor first; net cash
Emcure Pharma	9,204	+16.6%	1,746 (19.0%)	941 (10.2%)	20.1%	34.7x	≤18.6x	Medium: oncology/injectables; Canada/EU
Akums Drugs (CDMO)	4,359	+5.9%	522 (12.0%)	256 (5.9%)	8.5%	40.9x	≤21.4x	Scale CDMO; low margin

Peer RoE is as reported by Screener; Beta's is recomputed. market.md shows Beta at 40.6x / 21.5x on slightly different debt and cash inputs, reconciled here to ~41x / ~22x.

Beta vs each peer

Peer	Beta's strengths	Beta's weaknesses
Natco	Faster branded growth; no US litigation cliff; CDMO annuity	<1/10th the scale; no US/EU; margin 19.7% vs 35.9%; P/E 41x vs 13.5x
Shilpa	RoE ~19% vs 9%; lower P/E; domestic brand franchise	No EU/US sites, biologics or ADCs; Shilpa grew 3x faster at 28% margin
Venus	Stronger branded oncology; captive API; NDDS	Venus grew 18.8% vs 6.2%, is net cash, and trades at under half Beta's multiples
Emcure	Pure-play oncology; captive API	~24x larger; regulated markets; RoE 20%
Intas / DRL / Zydus	Agility; NDDS niche; existing supply relationships	No biosimilars or IO; smaller field force; no EU approval
Naprod / Celon / small CMOs	Listed capital; PE backing; LATAM approvals; API base	Similar cost structure; L1 pricing

Unlisted and large-cap competitors

Competitor	Type	Relevance
Intas (Accord)	Unlisted; #6 IPM; India ~42% / Europe ~40%	Major EU oncology injectables; biosimilars; historical Beta CDMO client
Dr Reddy's	Listed	Oncology BU, biosimilars, toripalimab
Zydus / Cadila	Listed	Biosimilars (Tishtha), chemo; historical client
Sun, Cipla, Glenmark, Alkem, Lupin, Torrent	Listed	Oncology divisions; Torrent a historical client
Hetero	Unlisted	Low-cost generics and tenders; historical client
Celon Labs (Kelix Bio since Nov 2020)	Unlisted	Oncology and critical care
Fresenius Kabi Oncology	MNC subsidiary	Cytotoxic API and injectables in the same Baddi cluster
Eugia (Aurobindo)	Listed parent	US/EU oncology injectables
Naprod / Mac-Chem	Unlisted	Integrated oncology API and formulation; closest analogue
Biocon Biologics	Listed parent	Oncology biosimilars
MNCs (Roche, AZ, BMS, MSD, Novartis, Pfizer)	Foreign	Patented targeted and IO drugs; customs waivers

Porter's Five Forces, barriers and moat

Force	Intensity	Rationale
Rivalry	High	Fragmented chemo generics; dozens of Baddi CMOs; many brands per molecule
Buyer power	High	Hospital chains, L1 tenders, large CDMO clients
Supplier power	Medium	API 65–70% captive, but China KSMs, platinum, vials
Substitutes	Medium-High	IO, ADCs and biosimilars displacing cytotoxics
New entrants	Medium	Containment capex and NGT approvals (3–5 yrs) vs easy contract manufacturing for marketers

Barriers to entry: cytotoxic manufacturing moderate-high; branded oncology moderate; tender exports low-moderate (2–4 yr registrations); CDMO low-moderate. Moat: narrow, medium durability, resting on API-to-formulation integration, cytotoxic-dedicated LATAM-approved plants, 85%+ hospital reach with long CDMO relationships, and an NDDS oral-liquid niche. It can be eroded by the TMR, biosimilar-led rivals, CDMO clients insourcing, and L1 pricing. Beta is a price-taker outside NDDS. [Analyst View]

Risks & Red Flags

#	Risk	Category	Severity	Explanation	Mitigant
1	NPPA 30% trade-margin cap on ~110 non-scheduled anti-cancer drugs	Regulatory	High	MRP cuts of 20–70% in Beta's channel. Branded is 36% of revenue at ~35% EBITDA. Hospitals that lose spread may push PTD down or switch brands; the cap favours higher-priced brands. Threatens the 20–25% branded growth guide. Likely trigger for the 12–13 Oct fall [Inferred]	Manufacturer realisation unchanged on paper; volume upside from affordability; Beta grew 36% after the 2019 cap
2	Supreme Court uniform 16% margin	Regulatory	Medium-High	Much harsher than 30%	Government's own proposal is 30%
3	Guidance credibility / execution	Execution	High	FY26 +6.2% vs 20–25%; exports ₹71 Cr vs "crossing ₹100 Cr"; EU-GMP slipped 5 times; ₹530 Cr FY27 quietly dropped	Q1 FY27 +25%; branded +47%; tenders awarded Mar-26
4	Export tender lumpiness / LatAm geopolitics	Business	High	₹20–25 Cr slipped; Q1 FY27 exports −47%; ~₹30 Cr/quarter needed	280+ registrations; 623 pipeline; ~50% of H1 orders in hand
5	Platin economics under ceilings	Business	Medium	<7% of revenue at 10–15% contribution; supply halted in H2 FY26	+50% ceiling revision Jun-26
6	Working capital / negative FCF	Financial	Medium-High	CCC 53 → 100 days; GCA 260–280 days; FCF −₹16 Cr; a CRISIL downgrade trigger	₹87 Cr net cash; limits ~16% utilised
7	Promoter selling before the guidance cut	Governance	High	1,85,115 sh (~₹31 Cr) sold on 13 Nov 2025, 6 days after the 7 Nov guidance trim and ~3 months before the Feb cut	Group still holds ~58.9%, unpledged
8	Supply overhang	Financial	Medium	PE ~6.4–6.7% tradeable since May-26; Nivian ~2.6% lock-in ends ~Oct–Nov 2026 [UNVERIFIED]; thin float	Holders at breakeven; no bulk exits so far
9	Disclosure / audit quality	Governance	Medium-High	₹4.2 lakh fee; no KAMs; split auditors; mixed metric definitions; subsidiaries' quarterlies unreviewed; UDIN omission	Unmodified opinions; PE board nominee
10	Idle raise / negative carry	Financial	Medium	80% of ₹117 Cr unused 16 months on; ₹9.36 Cr coupon; R&D centre abandoned	Converted to equity; Nivian funded
11	Profits in subsidiaries / transfer pricing	Governance	Low-Medium	~65% of PAT in subsidiaries; Adley Lab 69% intra-group; ₹16 Cr loans + ₹24.9 Cr guarantees	99.99% ownership
12	Nivian integration / valuation	Execution	Medium	~25x EBITDA for a company incorporated in 2024; 33.91% minority with no put/call	Founder retained; +45% growth
13	China KSM dependence	Macro	Medium	Export curbs or plant shutdowns	Captive API; KSM plant end-Q3 FY27
14	Competition / CDMO price erosion	Business	Medium-High	Clients who are also competitors may insource; CDMO guided at only 5–6%	NDDS; 20–25 launches
15	Therapeutic obsolescence	Business	Medium	Cytotoxic-heavy portfolio; biosimilars 3–4 years away	Cytotoxics remain backbone therapy
16	GMP / inspection	Regulatory	Medium	Adverse EU or LATAM findings would hit exports and CDMO	No critical observations to date
17	Valuation de-rating	Financial	Medium-High	41x P/E vs 12–35x for most peers	Q1 run-rate; FY27E EV/EBITDA ~17–18x
18	Key-person / family concentration; dual MD pay	Governance	Medium	Two promoter-brother MDs paid ₹3.02 Cr each; Neeraj Batra not a related party in the AR	Professional CFO
19	Land title (AFPL Barotiwala)	Governance / legal	Medium	Proprietorship-name title, writ pending; stamp duty unquantified; disclosure dropped in FY26	FY26 CARO says title is in the company's name
20	Rating divergence / CRISIL information advisory	Financial / governance	Medium	BBB+ vs A-; Brickwork INC until Jul-26 and also the monitoring agency	Low bank debt
21	Cytotoxic waste / ESG	ESG	Low-Medium	Effluent, worker safety, NGT permits	Brickwork ESG "Adequate"; CSR ₹50.4 lakh fully spent
22	Monsoon / labour disruption	Business	Low-Medium	15–20 days lost in H1 FY26	Multi-site
23	Unhedged FX	Macro	Low-Medium	18% exports; no hedging; FX gain ₹0.22 Cr	Natural hedge from imports; PCFC lines
24	Tax / litigation	Regulatory	Low	IT demand ₹0.92 Cr (AY21-22); advance-tax default; MSME interest	Small

Red flags at a glance: promoter sale before guidance cuts; dual MD pay; thin audit with no KAMs; idle CCD proceeds; WC blow-out and negative FCF; audited-vs-presented metric gap; CRISIL awaiting information; land-title disclosure dropped; Adley Lab transfer pricing; corporate guarantees missing from the CL note; ₹16.09 Cr land bought from an undisclosed seller; FY20 share issue unexplained.

Concall Highlights & Guidance

Calls held: 7 Nov 2024 (H1 FY25), 16 May 2025 (H2 FY25), 7 Nov 2025 (H1 FY26; PhillipCapital), 15 May 2026 (FY26). No call for Q3 FY26 (14 Feb 2026) or Q1 FY27 (results 20 Jul; deck 27 Jul 2026).

Call	Tone	Key numbers	Key guidance / quotes
H1 FY25, 7 Nov 2024	Confident	Revenue ₹180.3 Cr (+28%); EBITDA ₹40.31 Cr (22.36%); PAT ₹24.44 Cr (+23%); exports +141%; brands +30%; CDMO ₹72.7 Cr; derma ₹6.4 Cr (EBITDA −₹1.3 Cr); WC 86 days	"Grow at 25% to 30% for the next many years"; exports +50%/yr; derma ₹13 Cr → ₹26–30 Cr; COFEPRIS by Jan-25; EU-GMP before Mar-25; "don't need any funds till ₹450–500 Cr"
H2 FY25, 16 May 2025	Confident / expansive	Revenue ₹362.35 Cr; EBITDA ₹81.04 Cr mgmt (₹74.6 Cr audited); PAT ex-one-off ₹45.83 Cr; Mexico audit cost ₹7–8 Cr	"Double our sales in next 3 years"; "₹750 odd crores" by FY28; EBITDA 23–25%; exports to "triple"; analyst's ₹450 Cr not refuted; "nothing on the table" for M&A; migration in 2–3 months
H1 FY26, 7 Nov 2025	Cautious	Sales ₹204 Cr (+13%); EBITDA ₹47 Cr (23.08% mgmt); PAT ex-CCD ₹28.71 Cr (reported ₹23.9 Cr, −2%); GM 51.35%; OCF ~−₹37 Cr	Growth cut to 20–25%; "never gave ₹450 crores"; H2 exports "more than ₹100 Cr"; EU audit Jan–Mar 2026
Q3 FY26, 14 Feb 2026 (no call)	Defensive	Revenue ₹87.27 Cr (flat); PAT ₹8.51 Cr (−4.8%); employee cost +21%	FY26 cut from ₹420 Cr to ₹400 Cr; FY27 ₹530 Cr at ~24% EBITDA; methotrexate OS ₹13 Cr FY27; stock −19.55% to ₹1,105
FY26, 15 May 2026	Defensive / expansive	"Net revenue ₹396 Cr"; EBITDA ₹86.85 Cr (22.57%; 19.67% ex-OI); PAT ₹41.5 Cr	Vision 2030 ₹850–900 Cr; 20–25% growth; exports ₹105–110 Cr; did not confirm ₹530 Cr; EU audit Sep-26; platin "beyond control"; tender country "we don't want everyone to hear"
Q1 FY27, 20/27 Jul 2026 (deck only)	Upbeat	Revenue ₹125.5 Cr (+25%); EBITDA ₹27.4 Cr (21.83%); PAT ₹16.5 Cr (+41%)	"Vision 2030 remains on track"; 20–25% reiterated; "faster order inflows" in exports; stock +9–17% to ₹2,439

Guidance vs actual

Guided (date)	What was said	Actual	Verdict
Group growth (Nov-24)	25–30% for many years	FY25 +22.5%; FY26 +6.2%	Miss
FY26 revenue (May-25 → Feb-26)	₹750 Cr by FY28; ₹450 Cr not refuted → 20–25% → ₹420 Cr → ₹400 Cr	₹384.8 Cr	Large miss
FY26 EBITDA	23–25%	19.67% ex-OI (22.57% incl.)	Miss
H2 FY26 exports (Nov-25)	>₹100 Cr	~₹28 Cr	Severe miss
Exports "triple in 2–3 yrs" (May-25)	~₹240 Cr by FY27–28	₹71 Cr; Q1 ₹17.2 Cr	Off track
Q1 FY27 exports (May-26)	₹20–22 Cr	₹17.2 Cr	Miss
CDMO	+5–10%	+1% FY26; +41% Q1	Volatile
Branded oncology	~25% FY26	+20%; Q1 +47%	Near / beat
Derma revenue	₹26–30 Cr → ₹18–20 Cr	₹16.58 Cr; Q1 −6%	Miss
Derma breakeven	By Sep-25	H1 FY26 +₹11 lakh	Delivered
EU-GMP audit	Dec-23 → Mar-25 → Oct–Dec 25 → Jan–Mar 26 → Sep-26	Not confirmed	Slipped 5x
COFEPRIS	By Jan-25	Mar-25	Small slip
Main Board migration	Jul-24 → Jun–Aug 25	24 Nov 2025	~16 months late
Intermediate plant	6–8 months (Nov-25)	End-CY26 / end-Q3 FY27	Slipping
R&D centre (CCD use)	₹10–15 Cr	Land to be sold	Abandoned
CCD conversion	Jun-26	25 May 2026	Delivered
FY27 revenue	₹530 Cr @ ~24% (Feb-26)	"20–25%" ≈ ₹462–481 Cr (₹475–495 Cr on the ₹396 Cr base); Q1 run-rate ~₹502 Cr	Quietly lowered

Analyst Q&A that reveals risk

Theme	Exchange
Working capital (Nov-25; Rishikesh Raut, Avnish Burman)	H1 OCF ~−₹37 Cr; receivable days 104 → 108; management says it "tracks volume growth"
CDMO margin erosion (Aastha Jain)	Price erosion plus platin at 10–15% contribution; annualised exit impact ₹40–50 Cr (analyst)
Export opacity (May-26)	Tender value and country withheld; top-5 markets unnamed
₹450 Cr dispute (Pritesh, Lucky Investments)	Management denied a figure it had not refuted in May-25
Earnings quality	Other income ~₹11 Cr (~26% of PAT) inside the "22.57%" headline
Use of proceeds (Punit Mittal)	"Inorganic and biosimilars"; used for Nivian; no biosimilar partner yet
Interest reconciliation	"₹4 Cr monthly" question unresolved; CRISIL ~₹9.1 Cr/yr
Standalone margins (Avnish Burman)	Export plant carries regulatory costs ahead of revenue
Capacity	₹700–800 Cr potential vs lyophilisation at ~85%

Questioners included Stallion Asset, KSA, Leo Capital, EverFlow, Pkeday, Viakarya, NX Wealth, Gala Bros, Ebisu, Lucky Investments, Crown Capital, RatnaTraya, Ithought, FundVeda, Scientific Investing and NBG Invest. Pattern: the medium-term ambition (₹750 Cr FY28; ₹850–900 Cr FY30) never moves while near-term numbers are missed and blamed on outside factors. The headline metric changes from call to call (PAT ex-CCD; EBITDA incl. OI; "net revenue" incl. OI).

News timeline (Oct 2024 – Oct 2026)

Date	Event
7 Nov 2024	H1 FY25 results/call; 25–30% guide
8 Nov 2024	Edelweiss Buy, target ₹2,245 (pre-bonus)
12 Nov 2024	EGM approves preferential issue; SHA with HealthQuad/Inti
14 Nov 2024	NSE fine ₹10,000 (XBRL delay)
27 Nov 2024	₹117 Cr CCD allotment; Mahipal and Sehgal join the board
5–6 Feb 2025	Bonus 1:20; IDs Jain and Watts; Seema Chopra resigns; NSE clarification query
Mar 2025	COFEPRIS audit (~10 days lost); 27 Mar bonus allotment
16 May 2025	FY25 call: "₹750 Cr by FY28"
4 Aug 2025	CRISIL BBB+/Positive reaffirmed
5 Sep 2025	FY25 AR; 30 Sep 20th AGM (MD reappointments)
Sep 2025	GST cut; billing pause
7 Nov 2025	H1 FY26 call: guide cut to 20–25%
12–20 Nov 2025	NSE in-principle (NSE/LIST/274) and final (NSE/LIST/284) migration approvals
13 Nov 2025	Promoter Neeraj Batra sells 1,85,115 sh at ₹1,686; Airavat buys 1,55,925
24 Nov 2025	Main Board trading begins (+3% to ₹1,681 intraday on approval)
29 Nov 2025	42,337 CCDs converted (Generational)
9–12 Jan 2026	Nivian deal announced; ESOP; stock +4% to ₹1,653
20 Jan 2026	CRISIL BBB+/Positive reaffirmed
4 Feb 2026	EGM: Nivian swap, ESOP, authorised capital
14–16 Feb 2026	Q3 FY26; FY26 guide cut; stock −19.55% to ₹1,105
25 Feb 2026	52-week low ₹990.1
Mar 2026	Export tenders awarded ~4 months late; 16 Mar NSE reply on shareholding
Apr 2026	Azerbaijan GMP inspection (13–17); Philippines CPRs (22); mesotherapy approval; methotrexate OS launch; Vision 2030
25 Apr 2026	Nivian swap allotment 2,83,668 sh at ₹1,712.49
14–15 May 2026	FY26 results and call; monitoring-agency report
25 May 2026	6,65,314 CCDs converted
11 Jun 2026	NPPA +50% carboplatin/cisplatin ceilings
12–16 Jun 2026	20% upper circuit ~₹1,771; NSE volume query; MarketsMojo 47 → 57 (Hold)
6 Jul 2026	Brickwork A-/Stable assigned
20–23 Jul 2026	Q1 FY27 results; stock to ₹2,439; UDIN reply
12 Aug 2026	52-week high ₹2,807.9
18 Aug 2026	Board allots 35,383 bonus true-up shares
5 Sep 2026	FY26 AR (net cash ₹87.04 Cr) and AGM notice
22 Sep 2026	Azerbaijan product approvals
25 Sep 2026	CRISIL "awaiting adequate information"
29 Sep 2026	Supreme Court floats a 16% margin
30 Sep – 1 Oct 2026	21st AGM (all passed); trading window closed
8 Oct 2026	NPPA in-principle 30% trade-margin cap; MarketsMojo Hold reiterated
12–13 Oct 2026	Stock −4.6%, then −8.7/−9.5% to ₹1,669–1,684; no company announcement [trigger inferred: NPPA/SC]

Growth, Outlook & Valuation

Revenue visibility (no order book in pharma)

Vertical	Visibility proxy
CMO (39%)	104+ customers, 95% repeat; partner schedules; price-controlled
Exports (18%)	Tenders awarded Mar-26, supply from Q1 FY27; ~50% of H1 FY27 orders in hand (May-26); 280+ registrations; 623 pipeline; 43 approvals in H1 FY26; >200 dossiers in 18 months; ~100 registrations expected in FY27
Branded (36%)	Recurring prescriptions; 7 brands >₹5 Cr; new products 25%
Recurring share	~60–70% of revenue recurring by nature [Est.]; contracted share not disclosed

Expansion, pipeline and capex

Item	Plan / timeline
KSM/intermediate plant	~₹27 Cr; commercial end-CY26 / end-Q3 FY27; +1–1.5pp margin
Lyophilisers	2 more in the existing plant
Capex envelope	≤₹25 Cr over FY27–28; assets support ₹700–800 Cr revenue
Product launches	24 over FY27–29 (10/7/7); 8 oncology, 14 derma, 14 CMO, 3 API projects; imatinib OS; NDDS approval Jan–Feb 2027; methotrexate OS ₹13 Cr FY27
Markets	EU (after GMP); Algeria, Mexico, Philippines, Azerbaijan/CIS; Vietnam, Thailand
IVF	Recombinant in-licensing; 4 launches; corporate hospitals
Biosimilars	NDA stage; 3–4 years
Inorganic	"Open to acquisitions"

Management guidance and Vision 2030

Metric	FY27	Longer term
Group revenue	+20–25% (~₹462–481 Cr incl. Nivian); Feb-26 ₹530 Cr not confirmed	₹850–900 Cr FY30 (~₹750 Cr FY28 in the FY25 internal budget)
EBITDA	"23–24%" incl. other income	—
Exports	₹105–110 Cr	₹200–250 Cr FY28; 30% of mix FY30
Branded	+20–25%	51% of mix FY30
CDMO	+5–6%	13% of mix FY30
Derma	~+50%	>₹50 Cr in 3 years; meso-fills ₹50–100 Cr in 3–5 years
Nivian	+30% (~₹55–60 Cr)	—

Implied FY27 organic growth after Nivian is only ~5–10% [Est.]. No sell-side consensus exists.

Catalysts

Catalyst	Timing	Direction
Sep-26 shareholding pattern	~21 Oct 2026	Shows any PE/Nivian selling
NPPA final notification and DGHS drug list	Late Oct 2026	Risk
Supreme Court follow-up on the 16% margin	Pending	Risk
Q2 FY27 results (H1 call was 7 Nov last year)	Early–mid Nov 2026	Exports ~₹30 Cr/quarter needed; platin restart
EU-GMP outcome	Overdue since Sep-26	Re-rating if positive
KSM plant commissioning	End-Q3 FY27	+1–1.5pp margin
Nivian lock-in expiry	~Oct-26 to early 2027	Overhang
CRISIL rating action	Pending information	Either

Valuation

	Mar-23	Mar-24	Mar-25	Mar-26	3-yr avg	Now (13 Oct 26)
Price ₹ (bonus-adjusted)	597	1,175	1,906	1,387	—	1,669–1,684
FD market cap ₹ Cr	~603	~1,186	~2,058	~1,503	—	1,856–1,873
P/E (reported PAT)	19.6x	32.6x	48.5x	36.2x	39.1x	~41x (+4–5%)
P/E (CCD-adjusted PAT)	19.6x	32.6x	~42.7x	~31.0x	~35.4x	~36x
P/B (CCD as equity)	4.9x	7.5x	6.6x	4.2x	6.1x	~4.4x
P/B (reported)	4.9x	7.5x	9.8x	5.7x	7.7x	Screener 7.0–7.2x (stale)
EV/EBITDA	11.3x	19.5x	25.9x	18.7x	21.4x	~22x; ~20.4x with full-year Nivian
EV/Sales	2.6x	4.0x	5.3x	3.7x	4.3x	~4.4x
Dividend yield	0%	0%	0%	0%	0%	0%

EV build (₹ Cr)	Value
FD market cap (1,11,21,255 sh × ₹1,669–1,684)	1,856–1,873
+ Bank debt	~38
+ Unpaid CCD interest	~3
− Cash (after the ₹20.8 Cr Nivian payment)	~104
+ Nivian NCI	~36
EV	~1,829–1,846
÷ TTM EBITDA ₹83.3 Cr	~22x
FY27 guide: revenue ₹462–481 Cr, EBITDA ~₹102–106 Cr	~17–18x
Feb-26 guide (₹530 Cr @ 24%)	~14x

Scenarios (Aamara illustrative; not price targets)

Case	FY27E assumptions	Owners' PAT ₹ Cr	Implied P/E at ~₹1,870 Cr
Bull	₹481 Cr revenue, ~22.5% EBITDA; exports on track; EU-GMP cleared; limited NPPA hit	~65	~29x
Base	~₹470 Cr, ~21% EBITDA; exports ~₹90 Cr; some NPPA friction	~55–60	~31–34x
Bear	~₹430 Cr, ~19.5% EBITDA; export miss; PTD pressure from TMR	~45	~41x

All scenario figures are [Est.] / [Analyst View]. Investorstack's base case is FY30 revenue of ₹700–750 Cr vs management's ₹850–900 Cr.

Coverage and street sentiment

Source	View	Date
Edelweiss	Buy, ₹2,245 (pre-bonus; ~₹2,138 adjusted); earlier ₹1,600 (May-24, met), ₹1,325 (Sep-23, met), plant visit note Mar-23	8 Nov 2024 (stale)
MarketsMojo (quant)	Hold, score 57 (from 47): valuation "Very Expensive", quality "Average", trend "Positive", technicals "Mildly Bullish"	16 Jun; reiterated to 8 Oct 2026
Live sell-side consensus	None (0 Buy / 0 Hold / 0 Sell); Bitget "56 analysts" is an artefact	—
Trade Brains	Bullish ("DIIs nearly tripled")	29 Jun 2026
Investorstack	Balanced; management 4/5; bear case FY27 miss of 10–15%	16 Jun 2026
Multibagg / Arthneeti / Univest / Sahi	Mixed / neutral / bearish mood (Jun) / bullish (Sep)	2026
Tickertape / Sharpely	"Valuation high, entry bad" / QVM 62	—
ValuePickr (~159 posts)	Bull pranavpallod12 (platin revival, Q2 stronger); bears rjtjking ("eating more than they can chew"), aashu4uiit (Q3 miss), srinik1988 (MD pay, CDMO conflict), Shivamnag (ID independence, Beta UBK), Voldemort (no plant visit, exited)	2021–Jul 2026

Price path: ₹1,585 (9 Jan) → ₹1,105 (16 Feb) → ₹990 (25 Feb) → ~₹1,100 (Apr) → ₹2,250 (late Jun) → ₹2,808 (12 Aug) → ₹2,531 (14 Aug) → ₹2,195 (28 Aug) → ₹2,055 (18 Sep) → ₹1,950 (9 Oct) → ₹1,669–1,684 (13 Oct). The stock is back in the ₹1,575–1,712 smart-money entry band. The bear reading is that the Apr–Aug rally (+155%) was flow-driven; the bull reading is that Q2 benefits from platin and tender supply.

Final Verdict

Business Quality

Medium

Strong branded core (35–36% margin, +47%) inside low-margin CDMO and tender exports

Management Quality

Weak

Repeated guidance cuts, promoter sale before the cut, dual MD pay, ₹4.2 lakh audit

Financial Quality

Medium

Net cash ₹87 Cr; CCC 100 days; FY26 FCF −₹16 Cr

Valuation

Expensive

~41x P/E / ~22x EV/EBITDA; ~17–18x on FY27 guide

Overall View

Neutral

Wait for Q2 FY27, the NPPA notification and the EU-GMP outcome

Bull case

Branded oncology compounds at 20%+ with NDDS first-launches; gross margin holds above 56%.
Exports recover on delayed tenders, Azerbaijan/Philippines and EU-GMP, and platin revives after the +50% ceiling. Operating leverage plus zero CCD coupon lifts PAT ~40%.
Smart-money cost band (₹1,575–1,712) and net cash limit downside; FY27E EV/EBITDA ~17x.

Bear case

The NPPA 30% cap (or SC 16%) compresses hospital-channel economics just as branded becomes the growth engine.
Another export/EU-GMP miss confirms the guidance pattern; FY27 lands at ~₹430 Cr; the multiple de-rates toward Venus/Natco (13–18x).
Governance discount widens: overhang from PE/Nivian shares, CRISIL action, WC stretch, FCF still negative.

Base case (12–18 months): revenue ~₹460–480 Cr with ~10% organic growth plus Nivian, EBITDA ex-OI ~21%, owners' PAT ~₹55–60 Cr. The NPPA cap causes a quarter or two of trade disruption but no collapse in manufacturer realisation. The EU-GMP outcome is uncertain. The stock trades sideways in a wide band around the PE cost cluster until Q2/Q3 prove the export recovery. [Analyst View]

Five things to remember

Use audited figures: revenue ₹384.8 Cr and EBITDA 19.7%, not ₹396 Cr and 22.6%.
The promoter sold 1,85,115 shares at ₹1,686 on 13 Nov 2025 (AR-confirmed). The Jun-26 drop to 59.10% is dilution.
Branded oncology is the only line that consistently meets guidance; exports and EU-GMP consistently miss.
Cash conversion is poor: CCC 100 days, FY26 FCF −₹16 Cr, ₹93 Cr of the raise idle at Mar-26.
The MDs take ~₹3.02 Cr each across two entities (~16% of group PAT); audit fee ₹4.2 lakh; no KAMs.

Five questions before investing

What share of branded sales is in non-scheduled molecules caught by the NPPA 30% cap, and what is the PTD impact?
Did the EU-GMP inspection take place in Sep-26, and with what observations?
Why did the controlling promoter sell in Nov-25, and is any further selling planned?
Has the Barotiwala land title been mutated and stamp duty paid? What is the quantum?
What information is CRISIL awaiting, and why does the AR omit the CRISIL rating?

Bottom line: Beta owns a genuinely good, high-margin branded oncology franchise, but it sits inside a related-party-heavy group run by a management team that keeps missing its own numbers, with weak cash conversion and a new NPPA threat to its best channel. At ~41x trailing earnings, near the PE investors' entry price, we are Neutral. We would revisit after Q2 FY27, the NPPA final notification and a confirmed EU-GMP outcome. [Analyst View]

Sources

All sources accessed 13 Oct 2026; document dates are shown where known. Merged and de-duplicated from the financials, business, governance, governance_ar, market, narrative and heard inputs. AR figures were verified against governance_ar.md (a page-referenced AR extract); the beta_txt files were not re-grepped in this assembly step.

Annual reports and results filings

Document	Date	URL
FY26 Annual Report (21st), NSE	5 Sep 2026	https://archives.nseindia.com/annual_reports/AR_31535_BETA_2025_2026_A_10632227_05092026162411.pdf
FY26 Annual Report, company site	Sep 2026	https://www.betadrugslimited.com/wp-content/uploads/2026/09/ANNUAL-REPORT-2025-26-1.pdf
FY25 Annual Report (20th)	5 Sep 2025	https://archives.nseindia.com/annual_reports/SME_AR_28583_BETA_2024_2025_A_5408479_05092025164526.pdf
FY26 audited results	14 May 2026	https://nsearchives.nseindia.com/corporate/BETA_14052026151131_final_results.pdf
Q3 FY26 results and outlook	14 Feb 2026	https://nsearchives.nseindia.com/corporate/BETA_14022026133437_FINAL_RESULTS_DEC_NSE.pdf
Q1 FY27 results	20 Jul 2026	https://nsearchives.nseindia.com/corporate/BETA_20072026085813_financial_results_30_june_2026.pdf
FY23 results	8 May 2023	https://archives.nseindia.com/corporate/NSERESULTS_08052023131952.PDF
Company financial reports page	—	https://www.betadrugslimited.com/financial-reports/

Transcripts and presentations

Document	Date	URL
H1 FY25 transcript	14 Nov 2024	https://nsearchives.nseindia.com/corporate/BETA_14112024164049_TRANSCRIPTNSE.pdf
H2 FY25 transcript	23 May 2025	https://nsearchives.nseindia.com/corporate/BETA_23052025200932_concall_transcript.pdf
H1 FY26 transcript	13 Nov 2025	https://nsearchives.nseindia.com/corporate/BETA_13112025152041_TRANSCRIPT.pdf
Q4 FY26 transcript	22 May 2026	https://nsearchives.nseindia.com/corporate/BETA_22052026202630_transcript.pdf
Investor presentation Jul 2026	27 Jul 2026	https://nsearchives.nseindia.com/corporate/BETA_27072026212351_Beta_Drugs_Ltd_Investor_Presentation_July_26.pdf
Investor presentation May 2026	15 May 2026	https://nsearchives.nseindia.com/corporate/BETA_15052026084046_Investor_Presentation.pdf
Investor presentation Nov 2025	7 Nov 2025	https://nsearchives.nseindia.com/corporate/BETA_07112025091924_investor_presntation.pdf
Investor presentation May 2025	15 May 2025	https://nsearchives.nseindia.com/corporate/BETA_15052025214637_investor_presentation.pdf
Investor presentation May 2023	8 May 2023	https://archives.nseindia.com/corporate/BETA_08052023215830_Investorpresentation.pdf
Corporate presentation Dec 2021	3 Dec 2021	https://archives.nseindia.com/corporate/BETA_03122021182853_Corporatepresentation21.pdf
Valorem Q1 FY27 fact sheet	Jul 2026	https://www.valoremadvisors.com/assets/admin/fact_file/1785238923_Q1-FY27_Beta__fact_sheet_v3.pdf

NSE corporate filings

Filing	Date	URL
Board intimation (Adley Formulations from promoter)	27 Aug 2018	https://nsearchives.nseindia.com/corporate/BETA_27082018130543_NSELETTER_740.pdf
Board intimation (Neeraj Batra resignation)	27 Jul 2019	https://nsearchives.nseindia.com/corporate/BETA_27072019152410_nseletter_063.pdf
Board outcome (auditors, IDs)	20 Jul 2022	https://nsearchives.nseindia.com/corporate/BETA_20072022132130_nseoutcome.pdf
Promoter purchase intimation	25 Jan 2023	https://archives.nseindia.com/corporate/BETA_25012023090513_nseintimation.PDF
EGM notice (preferential)	19 Oct 2024	https://nsearchives.nseindia.com/corporate/BETA_19102024175500_EGMNOTICENSE.pdf
Board intimation (CCD)	22 Nov 2024	https://nsearchives.nseindia.com/corporate/BETA_22112024171338_bodintimationnse.pdf
Board outcome (CCD allotment)	27 Nov 2024	https://nsearchives.nseindia.com/corporate/BETA_27112024110646_outcomefinalnse.pdf
Board outcome (bonus, IDs, migration)	5 Feb 2025	https://nsearchives.nseindia.com/corporate/BETA_05022025131847_BODOUTCOME.pdf
NSE clarification	6 Feb 2025	https://nsearchives.nseindia.com/corporate/BETA_06022025173424_nseclarification.pdf
Bonus outcome	27 Mar 2025	https://nsearchives.nseindia.com/corporate/BETA_27032025100411_OUTCOME_BOD.pdf
In-principle migration approval	13 Nov 2025	https://nsearchives.nseindia.com/corporate/BETA_13112025151244_inprincipal_approval.pdf
Migration letter	21 Nov 2025	https://nsearchives.nseindia.com/corporate/BETA_21112025085523_migration_letter.pdf
CCD conversion outcome	29 Nov 2025	https://nsearchives.nseindia.com/corporate/BETA_29112025105502_bod_outcome.pdf
Board outcome (Nivian, ESOP)	9 Jan 2026	https://nsearchives.nseindia.com/corporate/BETA_09012026171445_board_outcome_final.pdf
Nivian acquisition disclosure	10 Jan 2026	https://nsearchives.nseindia.com/corporate/BETA_10012026184451_ACQUISITION.pdf
Nivian revised update	11 Jan 2026	https://nsearchives.nseindia.com/corporate/BETA_11012026102003_revised_update.pdf
EGM notice	12 Jan 2026	https://nsearchives.nseindia.com/corporate/BETA_12012026183256_EGM_NOTICE.pdf
EGM corrigendum	30 Jan 2026	https://nsearchives.nseindia.com/corporate/BETA_30012026175256_Corrigendum__1_.pdf
NSE reply (shareholding)	16 Mar 2026	https://archives.nseindia.com/corporate/BETA_16032026162212_NSE_REPLY.pdf
Reg 30 announcement	3 Apr 2026	https://nsearchives.nseindia.com/corporate/BETA_03042026102422_REG_30_ANNOUNCEMENT.pdf
Nivian swap allotment outcome	25 Apr 2026	https://nsearchives.nseindia.com/corporate/BETA_25042026135833_nse_outcome_final.pdf
Monitoring agency report	14 May 2026	https://nsearchives.nseindia.com/corporate/BETA_14052026161138_monitoring_agency_report.pdf
Statement of deviation	20 Jul 2026	https://nsearchives.nseindia.com/corporate/BETA_20072026150821_STATEMENT_OF_DEVIATION_AND_VARIATION.pdf
Reply to NSE (UDIN)	23 Jul 2026	https://nsearchives.nseindia.com/corporate/BETA_23072026103522_reply_to_nse.pdf
Board outcome (bonus true-up)	18 Aug 2026	https://nsearchives.nseindia.com/corporate/BETA_18082026120648_outcome_of_board_meeting.pdf
AGM notice	5 Sep 2026	https://nsearchives.nseindia.com/corporate/BETA_05092026161612_NOTICE_AGM_FINAL.pdf
AGM scrutiniser report	1 Oct 2026	https://nsearchives.nseindia.com/corporate/BETA_01102026155812_Scrutinizer_report_and_voting.pdf
Nifty index change on migration	20 Nov 2025	https://www.niftyindices.com/Press_Release/ind_prs20112025_1.pdf

Credit ratings

Document	Date	URL
CRISIL rationale	30 May 2019	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/Beta_Drugs_Limited_May_30_2019_RR.html
CRISIL rationale	13 Apr 2020	https://crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/Beta_Drugs_Limited_April_13_2020_RR.html
CRISIL rationale	4 Aug 2025	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/BetaDrugsLimited_August%2004_%202025_RR_374523.html
CRISIL rationale	20 Jan 2026	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/BetaDrugsLimited_January%2020_%202026_RR_387185.html
CRISIL rating update	25 Sep 2026	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/Beta%20Drugs%20Limited-RU-25-09-2026.pdf
Brickwork press release	6 Jul 2026	https://www.brickworkratings.com/Admin/PressRelease/Beta-Drugs-6July2026%20%20(1).pdf
IndiaBonds (CCD ISIN INE351Y08014)	—	https://www.indiabonds.com/bond-directory/INE351Y08014-beta-drugs-limited/

Financial databases, shareholding and flows

Source	URL
Screener consolidated / standalone	https://www.screener.in/company/BETA/consolidated/ ; https://www.screener.in/company/BETA/
Screener price API	https://www.screener.in/api/company/1274175/chart/?q=Price-DMA50-DMA200-Volume&days=1825&consolidated=true
MarketsMojo	https://www.marketsmojo.com/stocks-analysis/beta-drugs-1002857-1 ; https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-hold-by-marketsmojo-4218721 ; https://www.marketsmojo.com/news/result-analysis/beta-drugs-q1-fy27-stellar-7459-profit-surge-defies-industry-headwinds-4110793
Trendlyne	https://trendlyne.com/equity/bulk-block-deals/BETA/83050/beta-drugs-ltd/ ; https://trendlyne.com/research-reports/stock/83050/BETA/beta-drugs-ltd/ ; https://trendlyne.com/equity/insider-trading-sast/all/BETA/83050/beta-drugs-ltd/ ; https://trendlyne.com/conference-calls/83050/BETA/beta-drugs-ltd/ ; https://trendlyne.com/equity/corporate-actions/BETA/83050/beta-drugs-ltd/ ; https://trendlyne.com/portfolio/superstar-shareholders/53746/Q2-2026/ashish-kacholia/ ; https://trendlyne.com/portfolio/superstar-shareholders/53746/Q2-2021/ashish-kacholia/
Tijori	https://www.tijorifinance.com/company/beta-drugs-ltd/shareholding/
Value Research / Angel One / Upstox	https://www.valueresearchonline.com/stocks/202318/beta-drugs-ltd/shareholding/ ; https://www.angelone.in/stocks/beta-drugs-ltd/shareholding ; https://upstox.com/stocks/beta-drugs-limited-shareholding/ ; https://upstox.com/stocks/beta-drugs-limited-share-price
Insider aggregators	https://www.insiderscreener.com/en/company/beta-drugs-ltd ; https://www.marketscreener.com/insider/NEERAJ-BATRA-A29O0H/ ; https://in.marketscreener.com/insider/RAHUL-BATRA-A29O0J/ ; https://www.marketscreener.com/quote/stock/BETA-DRUGS-LIMITED-38123477/news/
IIFL	https://www.indiainfoline.com/company/beta-drugs-ltd/reports/directors-report ; https://www.indiainfoline.com/company/beta-drugs-ltd/summary ; https://www.indiainfoline.com/company/beta-drugs-ltd/corporate-action ; https://www.indiainfoline.com/company/beta-drugs-ltd/management-discussions/71606
Other price/profile pages	https://www.business-standard.com/markets/beta-drugs-ltd-share-price-71606.html ; https://www.business-standard.com/companies/quarterly-results/beta-drugs-ltd-quarterly-results-71606 ; https://www.bajajfinserv.in/investments/beta-share-price ; https://choiceindia.com/stocks/beta-drugs-ltd-share-price ; https://www.icicidirect.com/stocks/beta-drugs-ltd-share-price ; https://anandrathi.com/stocks/beta-drugs-ltd ; https://www.share.market/stocks/beta-drugs-ltd-share/news ; https://www.tickertape.in/stocks/beta-drugs-BTAD ; https://stocks.zerodha.com/stocks/beta-drugs-BTAD ; https://sharpely.in/stocks/beta/analysis ; https://www.stockopedia.com/share-prices/beta-drugs-NSI:BETA/ ; https://www.emkayglobal.com/company-info/company-news/beta-drugs-ltd ; https://www.arihantcapital.com/company-information/board-of-directors/71606 ; https://www.cholasecurities.com/stock-market/beta-drugs-ltd/71606 ; https://www.infyner.com/company/beta-drugs/L24230HP2005PLC028969 ; https://www.chittorgarh.com/ipo/beta-drugs-ipo/743/
Company website	https://www.betadrugslimited.com/core-team/ ; https://www.betadrugslimited.com/news/beta-drugs-limited-set-to-acquire-66-09-stake-in-nivian-lifesciences-private-limited/

News, blogs and forums

Topic	URL
Mainboard migration	https://hdfcsky.com/news/beta-drugs-secures-nse-mainboard-approval-to-begin-trading-from-november-24 ; https://www.business-standard.com/markets/news/beta-drugs-up-3-percent-on-approval-to-migrate-shares-from-sme-to-mainboard-125112100426_1.html
₹117 Cr raise	https://cwv.yourstory.com/hindi/oncology-company-beta-drugs-raises-inr-117cr-from-healthquad-and-others-to-accelerate-growth-plans ; https://biospectrumindia.com/news/86/25396/oncology-company-beta-drugs-raises-rs-117-cr-from-healthquad-and-others-to-accelerate-growth-plans.html ; https://india.entrepreneur.com/news-and-trends/healthquad-leads-inr-117-cr-investment-in-beta-drugs-for/483593 ; https://biovoicenews.com/beta-drugs-raises-inr-117-crore-from-healthquad-others-to-accelerate-growth-plans/ ; https://news.ventureintelligence.com/private-equity/oncology-formulation-maker-beta-drugs-raises-rs.117-cr-from-healthquad ; https://www.tipranks.com/news/company-announcements/beta-drugs-ltd-approves-equity-share-allotment ; https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1142338/beta-drugs-clarifies-preferential-issue-impact-on-shareholding-pattern/
Nivian	https://scanx.trade/stock-market-news/orders-deals/beta-drugs-acquires-66-stake-in-ivf-specialist-nivian-lifesciences-for-69-4-crore/29756785 ; https://scanx.trade/stock-market-news/orders-deals/beta-drugs-to-acquire-66-09-stake-in-nivian-life-sciences-for-694-million/29509053 ; https://tradebrains.in/pharma-stock-jumps-4-after-announcing-plans-to-acquiring-66-stake-in-nivian-lifesciences/
Results coverage	https://www.multibagg.ai/market-pulse/articles/beta-fy26-94125 ; https://scanx.trade/stock-market-news/companies/beta-drugs-net-profit-rises-40-9-in-q1fy27/46122790 ; https://scanx.trade/stock-market-news/companies/beta-drugs-reports-fy26-consolidated-revenue-of-rs-396-0-crores-ebitda-margins-expand-to-22-6/40365592 ; https://tradebrains.in/beta-drugs-shares-soar-17-after-q1-pat-jumps-41-and-margin-expansion/ ; https://tradebrains.in/?p=127788 ; https://univest.in/blogs/beta-drugs-share-price-soars-q1-results-21-july-2026 ; https://univest.in/blogs/why-is-beta-drugs-share-price-falling ; https://tradebrains.in/multibagger-ashish-kacholia-stock-in-which-diis-nearly-tripled-their-stake-to-keep-on-your-radar/ ; https://scanx.trade/stock-news/beta-drugs-ltd
Regulatory milestones	https://scanx.trade/stock-market-news/companies/beta-drugs-limited-reaches-key-regulatory-milestones-in-azerbaijan-and-the-philippines/38376177 ; https://www.sahi.com/news/beta-drugs-gets-azerbaijan-approval-for-oncology-products-aiming-for-sales-in-fy27
Arthneeti summaries	https://www.arthneeti.com/stocks/beta-drugs-ltd/concall/q4-fy26-earnings-call-analysis ; https://www.arthneeti.com/stocks/beta-drugs-ltd/concall/q4-fy25-earnings-call-analysis ; https://www.arthneeti.com/stocks/beta-drugs-ltd/concall/q2-fy25-earnings-call-analysis ; https://www.arthneeti.com/insights/beta-drugs-ltd-q2-fy26-earnings ; https://www.arthneeti.com/insights/beta-drugs-ltd-q4-fy26-earnings ; https://www.arthneeti.com/insights/beta-drugs-ltd-q1-fy27-earnings
Bonus / founder	https://www.goodreturns.in/personal-finance/investment/bonus-share-alert-1-20-ratio-record-date-march-26-will-the-pharma-stock-spark-a-fresh-upside-rall-1413459.html ; https://in.marketscreener.com/quote/stock/BETA-DRUGS-LIMITED-38123477/news/Beta-Drugs-Limited-Announces-Demise-of-Vijvay-Kumar-Batra-Managing-Director-and-Announces-Executive-33547738/
Investorstack / ValuePickr	https://investorsstack.substack.com/p/beta-drugs ; https://forum.valuepickr.com/t/beta-drugs-limited/67797 (pages 5–8)
Airavat	https://inc42.com/?p=402862 ; https://esi.in/finance/investments/sebi/alternative-investment-funds/airavat-capital-trust/
Other	https://india.entrepreneur.com/?p=1392

Policy, industry and peers

Topic	URL
NPPA trade-margin cap (8 Oct 2026)	https://www.businesstoday.in/industry/pharma/story/cancer-drugs-may-get-cheaper-as-govt-set-to-cap-trade-margins-at-30-560489-2026-10-08 ; https://medicaldialogues.in/news/industry/pharma/cancer-drug-mrps-could-fall-20-70-under-nppas-proposed-trade-margin-cap-180844 ; https://www.theweek.in/news/health/2026/10/08/cancer-drug-prices-set-to-fall-government-caps-trade-margins-at-30-per-cent-of-mrp.html ; https://www.kotakneo.com/news/regulations/anti-cancer-drug-price-cap-hospital-pharma-stocks/ ; https://tradebrains.in/indian-markets/cancer-drug-price-cap-7-pharma-and-hospital-stocks-that-could-be-affected-by-the-30-trade-margin-limit-12659342 ; https://www.business-standard.com/amp/health/govt-submits-proposal-cap-trade-margins-anti-cancer-drugs-30-percent-mrp-126101200603_1.html
Supreme Court (29–30 Sep 2026)	https://www.businesstoday.in/india/story/this-is-carnage-sc-questions-rs-27000-mrp-on-rs-2700-cancer-drug-at-corporate-hospital-558585-2026-09-29 ; https://www.onmanorama.com/news/india/2026/09/30/supreme-court-uniform-medicine-margin.html ; https://newsonair.gov.in/sc-raises-concern-over-steep-markups-on-cancer-medicines-by-private-hospitals/
Ceiling prices	https://cliniexperts.com/regulatory-update/notification-for-revision-in-ceiling-price-of-carboplatin-10mg-ml-and-cisplatin-1mg-ml-under-para-19-based-on-the-decision-of-147th-authority-meeting-held-on-11-06-2026/ ; https://biovoicenews.com/nppa-fixed-ceiling-prices-of-131-scheduled-anticancer-formulations-under-nlem-minister/ ; https://medicaldialogues.in/news/industry/pharma/nppa-revises-ceiling-prices-of-138-essential-drugs-with-wpi-linked-hike-effective-april-1-167836
Budget / Schedule M / UCPMP	https://www.newsonair.gov.in/basic-customs-duty-exempted-on-17-drugs-and-medicines-for-cancer-patients-in-budget-2026-27 ; https://www.businesstoday.in/amp/industry/pharma/story/will-union-budget-2026s-cancer-drug-duty-cuts-actually-lower-treatment-costs-514942-2026-02-06 ; https://knnindia.co.in/news/newsdetails/msme/govt-considers-1-year-extension-for-small-pharma-firms-ahead-of-schedule-m-2026-rollout ; https://lexplosion.in/health-ministry-extends-schedule-m-compliance-deadline-for-small-and-medium-manufacturers-with-turnover-below-rs-250-crores-to-31st-december-2025/ ; https://www.nishithdesai.com/research-and-articles/hotline/pharma-healthcare-update/regulatory-wrap-2024-pharmaceutical-industry-in-india-15245
Pharmarack / market	https://www.biospectrumindia.com/news/73/28275/ipm-records-12-1-value-growth-in-july-2026-led-by-anti-diabetics-and-anti-neoplastics-pharmarack.html ; https://www.biospectrumindia.com/news/16/27451/ipm-records-positive-momentum-across-therapies-in-feb-2026-pharmarack.html ; https://www.biospectrumindia.com/news/16/27804/indian-pharmaceutical-market-crosses-rs-21745-crore-with-10-3-per-cent-growth-in-april-2026.html ; https://www.biospectrumindia.com/news/16/28097/indian-pharma-market-grows-13-3-in-june-monthly-sales-cross-rs-21400-cr-pharmarack.html ; https://www.business-standard.com/industry/news/ipm-volume-growth-at-3-4-marks-2-yr-high-on-steady-demand-across-therapies-126100800747_1.html ; https://www.biospectrumindia.com/news/16/27157/indian-pharma-market-to-see-growth-rate-of-7-88-1-in-2026-pharmarack.html ; https://www.marknteladvisors.com/research-library/india-cancer-treatment-market.html ; https://www.technavio.com/report/oncology-market-industry-in-india-analysis ; https://www.imarcgroup.com/india-oncology-market ; https://ijmr.org.in/cancer-incidence-estimates-for-2022-projection-for-2025-result-from-national-cancer-registry-programme-india/ ; https://rsdebate.nic.in/bitstream/123456789/757909/1/PQ_267_04022025_U277_p435_p436.pdf
Peers	https://www.screener.in/company/NATCOPHARM/consolidated/ ; https://www.screener.in/company/SHILPAMED/consolidated/ ; https://www.screener.in/company/VENUSREM/consolidated/ ; https://www.screener.in/company/EMCURE/consolidated/ ; https://www.screener.in/company/AKUMS/consolidated/ ; https://www.icra.in/Rating/GetRationalReportFilePdf?id=138894 ; https://www.icra.in/Rating/ShowRationalReportFilePdfViewer/93335 ; https://www.indianpharmapost.com/news/natco-pharmas-q1-fy27-revenue-falls-43-yoy-as-one-off-gains-fade-21382 ; https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3419166:0-natcopharm-fy26-revenue-hit-inr-43-759-mn-with-strong-export-growth-and-strategic-r-d-investments/ ; https://nsearchives.nseindia.com/corporate/SHILPAMED_22052026152241_Investor_presentation.pdf ; https://www.sahi.com/news/shilpa-medicare-launches-global-gmp-oncology-facility-to-expand-cdmo-capacity-by-35-2039-PE1_COR ; https://www.sahi.com/news/venus-remedies-q4-profit-surges-126-to-47-5-cr-as-margins-expand-956-bps-1907-PE1_COR ; https://www.sahi.com/news/venus-remedies-secures-1st-global-saudi-fda-approval-for-plerixafor-oncology-treatment-1907-PE1_COR ; https://www.cbinsights.com/company/celon-labs ; https://www.cphi-online.com/product/naprod-antineoplastic-formulation-injectable-oral-solid-propofol-general-lyophilised/ ; https://live-next.indiainfoline.com/company/fresenius-kabi-oncology-ltd/summary

Gaps noted by the inputs: ICRA/CARE/India Ratings not swept; the PIT Reg 7(2) filing and HealthQuad SHA not retrieved; Q2 FY27 not yet reported; EU-GMP outcome and the cause of the 12–13 Oct fall not established; Q3 FY26 and Q1 FY27 had no transcripts.